



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 5 : C07D 471/04, C07H 15/26, A61K 31/435, 31/495, 31/505, 31/70 // (C07D 471/04, 221:00, 221:00) (C07D 471/04, 241:00, 221:00)</p>		<p>A1</p>	<p>(11) International Publication Number: WO 95/00511</p> <p>(43) International Publication Date: 5 January 1995 (05.01.95)</p>
<p>(21) International Application Number: PCT/EP94/01923</p> <p>(22) International Filing Date: 10 June 1994 (10.06.94)</p> <p>(30) Priority Data: 9312891.6 22 June 1993 (22.06.93) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): THE BOOTS COMPANY PLC [GB/GB]; 1 Thane Road West, Nottingham NG2 3AA (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): ARMITAGE, Bernard, John [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham NG2 3AA (GB). LESLIE, Bruce, William [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham NG2 3AA (GB). MILLER, Thomas, Kerr [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham NG2 3AA (GB). MORLEY, Christopher [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham NG2 3AA (GB).</p>		<p>(74) Agent: MILLER, Thomas, Kerr; The Boots Company plc, Patents Dept., R4 Pennyfoot Street, Nottingham NG2 3AA (GB).</p> <p>(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY</p> <p>(57) Abstract</p> <p>Compounds of formula (I) and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C-R₃; R₁ represents hydrogen, halo, alkyl, hydroxy, carboxyalkenyl, alkoxycarbonylalkenyl, hydroxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, halogenated alkyl, carboxy, alkoxycarbonyl, alkanoylamino or carbamoylalkenyl; R₂ represents hydrogen, alkyl, halo, alkoxy, hydroxy, alkanoyloxy, or phenoxy; R₃ represents hydrogen or alkyl; R₄ represents hydrogen, halo, alkoxycarbonyl, cyano, benzyloxycarbonyl, alkanoyl, benzoyl, alkyl, carboxy, alkylthio or carbamoyl; R₅ represents hydrogen or alkyl; R₆ represents hydrogen or alkyl; R₁₀ represents phenyl, pyridyl or pyrimidinyl substituted by OR₆ and optionally further substituted wherein R₆ represents hydrogen, alkyl, alkoxy, carbamoyl, alicyclic hydrocarbon, phenyl, cycloalkylalkyl, arylalkyl or pyridyl; or when R₁₀ represents phenyl, OR₆ represents a monosaccharide group or a disaccharide group; which are antirheumatic agents. Compositions containing these compounds and processes to prepare them are also disclosed.</p>			
<p style="text-align: right;">(I)</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CONDENSED 4-AMINOPYRIDINES WITH ANTRHEUMATIC ACTIVITY

The present invention relates to therapeutic agents, and in particular to substituted ring-fused 4-aminopyridines, to processes for their preparation, to pharmaceutical compositions containing them and to their therapeutic activity as anti-rheumatic agents.

Rheumatoid arthritis is currently treated with anti-inflammatory agents, which alleviate the symptoms but do not affect the progression of the condition, or with disease-modifying antirheumatic drugs e.g. gold compounds, D-penicillamine, sulphasalazine, azathioprine and methotrexate. However, most disease-modifying antirheumatic drugs are associated with side-effects, often of a serious nature. This means that such drugs are often only used as a last resort in the most serious cases. Consequently a need exists for a less toxic, disease-modifying, antirheumatic drug which may be administered orally.

EP 0,361,177 discloses compounds of formula A



A


in which R represents alkyl, cyclopropyl, methylamino and p-fluorophenyl; R₁ represents hydrogen or a C₁₋₂ alkyl group; R₂ represents halo and A represents -CH- or -N-. It is disclosed that these compounds may be used to treat rheumatoid arthritis by intra-articular administration.

- 2 -

Japanese patent application number 38774/69, publication number J47-29519 (1972) discloses ethyl 4-anilino-7-methyl-1,8-naphthyridine-3-carboxylate amongst a number of compounds which are prepared as 5 intermediates for use in the preparation of anti-bacterial agents. It is suggested that these intermediates possess anti-bacterial and antiprotozoal activity but no results are given.

10 2-Diethylaminomethyl-4-(7'-methyl-1',8'-naphthyridin-4'-ylamino)phenol and 2-diethylaminomethyl-4-(1',8'-naphthyridin-4-ylamino)phenol are disclosed in the Australian Journal of Chemistry, 1984, 37, 1065 as having minimal antimalarial activity.


WO 86/06718 discloses compounds of formula B



15 in which X represents halo or haloalkyl; Y represents -CH- or -N-; and R₁, R₂ represent hydrogen or various substituted aminoalkyl substituents in which R₁ and R₂ are not both hydrogen. The compounds are claimed to have antimalarial activity. Certain compounds of 20 formula B in which R₁ and R₂ are both hydrogen are disclosed as intermediates.

Our co-pending application PCT/EP92/02901 (WO 93/13097) discloses compounds of formula C


- 3 -



C

All compounds disclosed in that application are disclaimed from this present application.

The present invention relates to compounds of formula I



I

- 5 and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C-R₃;

R₁ represents hydrogen, halo, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄ alkenyl group;

R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which may be substituted by a C₁₋₆ alkanoyloxy group), or a

- 4 -

phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);


R₃ represents hydrogen or a C₁₋₄ alkyl group;

R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, cyano, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkyl group [optionally 5 substituted by one or more hydroxy groups and/or an amino group of formula -NR_xR_y (in which R_x and R_y independently represent hydrogen or a C₁₋₄ alkyl group or R_x and R_y together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine 10 ring or a piperidine ring)], a carboxy group, a C₁₋₆ alkylthio group or a carbamoyl group of formula -CONR_aR_b [in which R_a and R_b independently represent hydrogen, a C₁₋₆ alkyl group (optionally substituted by an amino 15 group of formula -NR_cR_d in which R_c and R_d independently represent hydrogen or a C₁₋₄ alkyl group or R_c and R_d together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a 20 piperidine ring) or R_a and R_b together with the nitrogen atom to which they are attached form a pyrrolidine ring, 25 a morpholine ring or a piperidine ring];


R₅ represents hydrogen or a C₁₋₄ alkyl group;

R₉ represents hydrogen or a C₁₋₄ alkyl group;


R₁₀ represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

- 5 -

in which

- R₆ represents hydrogen, a C₁₋₆ alkyl group (optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C₂₋₇ alkoxycarbonyl group or a carbamoyl group of formula CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring)); a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or an arylalkyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo);
- or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and
- R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxycarbonyl group;

with a first proviso that when

- 6 -


R₁ represents hydrogen, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxy carbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxy carbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxy carbonyl group or a C₁₋₆ alkanoylamino group; and

R₂ represents hydrogen, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group, or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

R₄ represents hydrogen, halo, a C₂₋₇ alkoxy carbonyl group, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), carbamoyl, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ hydroxyalkyl group or a C₁₋₆ alkylthio group; and

R₅ represents hydrogen or a C₁₋₄ alkyl group; and

R₁₀ represents a group of formula (1)



(1)

in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl

- 7 -

group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or a benzyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

R₇ represents hydrogen, halo, trifluoromethyl,
10 trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, or a C₁₋₆ alkoxy group; and

R₈ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

15 R₉ represents hydrogen or a C₁₋₄ alkyl group
and B represents N

then A is other than CR₃ in which R₃ represents hydrogen or a C₁₋₄ alkyl group

20 and a second proviso that when A represents N and B represents CH; R₁ represents halo or a halogenated C₁₋₆ alkyl group; and R₂, R₄, R₅ and R₉ each represent hydrogen then R₁₀ is other than 4-hydroxyphenyl.


It will be understood that an alkyl group containing 3 or more carbon atoms may be straight or branched, for example, propyl includes n-propyl and isopropyl and butyl includes n-butyl, sec-butyl, isobutyl and tert-butyl. Alicyclic groups may be bridged.

In the present invention the phrase "a
30 monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation;

- 8 -

oxidation followed by esterification; esterification or acetalisation); is used to indicate that the monosaccharide or disaccharide has been derivatised in one of the following ways. Firstly, the 6-position of
 5 the saccharide may be oxidised to give the corresponding 6-carboxylic acid e.g. glucose may be oxidised to give glucuronic acid or a hydroxyl group on the saccharide may be oxidised to give a keto-sugar. Secondly, a carboxylic acid produced by oxidation may be esterified
 10 by methods known to those skilled in the art. Thirdly, a free hydroxy group on the saccharide may be esterified by treatment with an organic acid or an organic acid derivative. Fourthly, hydroxy groups on adjacent carbon atoms of the saccharide may be reacted with an aldehyde
 15 or a ketone to give an acetal or a ketal.

A preferred group of compounds of formula I is represented by formula IIa



in which

R₁ represents hydrogen, halo, a C₁₋₆ alkyl group,
 20 hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxy carbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxy carbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxy carbonyl group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄ alkenyl group;


R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ alkoxy group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which may be

- 9 -


substituted by a C₁₋₆ alkanoyloxy group), or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);

R₄ represents hydrogen, carbamoyl, a C₂₋₇ alkoxycarbonyl group or cyano; and


R₁₀ represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, 10 halo, an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C₂₋₇ alkoxycarbonyl group or a carbamoyl group of formula CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or an arylalkyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), or a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo);

- 10 -

or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and

R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxycarbonyl group.

10 In preferred compounds of formula IIa the preferred values for groups R₁, R₂, R₄ and R₁₀ are listed below.

Preferably R₁ represents hydrogen or chloro. More preferably R₁ represents hydrogen.


15 Preferably R₂ represents hydrogen, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group (for example methoxy, ethoxy, propoxy or butoxy), or phenoxy. More preferably R₂ represents hydrogen, ethyl, ethoxy, or phenoxy. Most preferably R₂ represents ethoxy.

20 Preferably R₄ represents hydrogen or a C₂₋₅ alkoxycarbonyl group (for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or butoxycarbonyl). More preferably R₄ represents a C₂₋₄ alkoxycarbonyl group. Most preferably R₄ represents ethoxycarbonyl.

25 More preferably R₁₀ represents 4-methoxyphenyl, 4-(2-pyridyloxyphenyl), 2-ethoxy-5-pyridyl, 4-(2-hydroxyethoxy)phenyl, [4-(β-D-galactopyranosyl)phenyl, 4-(2,3-dihydroxypropoxy)phenyl or 3-ethoxycarbonyl-4-hydroxyphenyl. Most preferably R₁₀ represents 4-methoxyphenyl.

30 A second preferred group of compounds of formula I is represented by formula IIb

- 11 -




in which

R_1 represents hydrogen, a C_{1-4} alkyl group, a C_{1-4} alkoxy group or a carbamoyl C_{2-4} alkenyl group;


R_2 represents hydrogen, a C_{1-4} alkoxy group or
5 acetoxyacetoxy;

R_4 represents hydrogen, a C_{2-7} alkoxycarbonyl group,
cyano or carbamoyl;


R_{10} represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

in which

10 R_6 represents hydrogen, a C_{1-6} alkyl group [optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula- $NR_{12}R_{13}$ (in which R_{12} and R_{13} independently represent hydrogen or a C_{1-4} alkyl group or R_{12} and R_{13} together with the nitrogen atom to
15 which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C_{2-7} alkoxycarbonyl group or a carbamoyl group of formula $CONR_{14}R_{15}$ (in which R_{14} and R_{15} independently represent hydrogen or a C_{1-6} alkyl group or R_{14} and R_{15} together

- 12 -

with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring); a C₃-12 alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁-4 alkyl group,
5 halo or a C₁-4 alkoxy group), a C₃-6 cycloalkyl C₁-4 alkyl group or an arylalkyl group (optionally substituted by a C₁-4 alkyl group, halo or a C₁-4 alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C₁-4 alkyl group, a C₁-4
10 alkoxy group, hydroxy or halo);

or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by
15 esterification; esterification or acetalisation); and

R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁-6 alkyl group, a carboxy group, a C₁-6 alkoxy group, or a C₂-7 alkoxycarbonyl group.

20 In preferred compounds of formula IIb the preferred values of R₁, R₂, R₄ and R₁₀ are listed below.

Preferably R₁ represents hydrogen, a C₁-3 alkyl group or a C₁-3 alkoxy group. More preferably R₁ represents hydrogen, methyl, ethyl or ethoxy. Most
25 preferably R₁ represents methyl.


Preferably R₂ represents a C₁-4 alkoxy group. More preferably R₂ represents ethoxy or propoxy. Most preferably R₂ represents ethoxy.

30 Preferably R₄ represents cyano, carbamoyl or a C₂-5 alkoxycarbonyl group. More preferably R₄ represents a C₂-5 alkoxycarbonyl group. More preferably R₄ represents ethoxycarbonyl.

- 13 -

Preferably R_{10} represents 4-methoxyphenyl, 6-ethoxy-3-pyridyl, 6-hydroxy-3-pyridyl, 6-ethoxy-2-pyridyl, 4-(carbamoylmethoxy)phenyl, 2,4-dihydroxy-5-pyrimidinyl, 2-(pyrid-3-yloxy)pyrid-5-yl, 2-phenoxy-5-pyridyl, 4-(ethoxycarbonylmethoxy)phenyl, 3-ethoxy-carbonyl-4-hydroxyphenyl, 4-(2-pyridyloxy)phenyl, 4-(β -D-lactopyranosyl)phenyl or 4-(β -D-galactopyranosyl)-phenyl.

A third group of preferred compounds of formula I
10 is represented by formula IIc



in which

R_1 represents hydrogen, a C_{1-4} alkyl group or a C_{1-4} alkoxy group;

R_2 represents hydrogen or C_{1-4} alkoxy group; and

15 R_4 represents hydrogen or a C_{2-5} alkoxycarbonyl group.

A preferred group of compounds of formula IIc is now given.


Preferably R_1 represents hydrogen or a C_{1-4} alkyl group. More preferably R_1 represents methyl.

20 Preferably R_2 represents hydrogen, methoxy, ethoxy or propoxy. More preferably R_2 represents ethoxy.

- 14 -

Preferably R₄ represents hydrogen, methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl. More preferably R₄ represents ethoxycarbonyl.

A fourth group of preferred compounds of formula I
5 is represented by formula IIId



in which

R₁ represents hydrogen, a C₁₋₄ alkyl group or a C₁₋₄ alkoxy group;

10 R₂ represents hydrogen or a C₁₋₄ alkoxy group;
R₄ represents hydrogen or a C₂₋₅ alkoxy carbonyl group and

R₆ represents hydrogen or a C₁₋₄ alkyl group.

A preferred group of compounds of formula IIId is now given.

15 Preferably R₁ represents hydrogen, methyl, ethyl or ethoxy. More preferably R₁ represents methyl.

Preferably R₂ represents hydrogen, methoxy, ethoxy or propoxy. More preferably R₂ represents ethoxy.

20 Preferably R₄ represents hydrogen, methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl. More preferably R₄ represents hydrogen or ethoxycarbonyl.

Preferably R₆ represents hydrogen, methyl, ethyl or propyl. More preferably R₆ represents ethyl.

- 15 -

Specific compounds of formula I are:

- ethyl 6-ethoxy-4-(4-methoxyanilino)-1,5-naphthyridine-3-carboxylate
- 5 ethyl 6-ethoxy-4-[4-(2-diethylaminoethoxy)anilino]-1,5-naphthyridine-3-carboxylate
- ethyl 6-methoxy-4-(4-methoxyanilino)-1,5-naphthyridine-3-carboxylate
- 10 ethyl 6-ethoxy-4-[4-(2-pyridyloxy)anilino]-1,5-naphthyridine-3-carboxylate
- ethyl 6-ethoxy-4-(2-ethoxy-5-pyridylamino)-1,5-naphthyridine-3-carboxylate
- 15 ethyl 6-ethoxy-4-[4-(2-hydroxyethoxy)anilino]-1,5-naphthyridine-3-carboxylate
- ethyl 6-ethoxy-4-[4-(β -D-galactopyranosyl)anilino]-1,5-naphthyridine-3-carboxylate
- ethyl 4-(4-methoxyanilino)-6-phenoxy-1,5-naphthyridine-3-carboxylate hydrochloride
- 7-chloro-4-(4-methoxyanilino)-1,5-naphthyridine
- 20 ethyl 6-ethyl-4-(4-methoxyanilino)-1,5-naphthyridine-3-carboxylate
- ethyl 6-ethoxy-4-[4-(2,3-dihydroxypropoxy)anilino]-1,5-naphthyridine-3-carboxylate
- ethyl 3-ethoxy-8-(4-methoxyanilino)-pyrido[2,3-b]pyrazine-7-carboxylate
- 25 ethyl 5-(6-ethoxy-3-ethoxycarbonyl-1,5-naphthyridin-4-ylamino) salicylate
- 5-(4-methoxyanilino)-2-methyl-1,8-naphthyridin-3-yl acetoxymethyl ester
- 30 ethyl 7-(2-carbamoylvinyl)-6-ethoxy-4-(4-methoxyanilino)-1,8-naphthyridine-3-carboxylate
- ethyl 6-ethoxy-4-(2-ethoxy-5-pyridylamino)-7-methyl-1,8-naphthyridine-3-carboxylate
- 5-(3-ethoxy-2-methyl-1,8-naphthyridin-5-ylamino)pyridin-2-ol
- 35 3-ethoxy-5-(2-ethoxy-5-pyridylamino)-2-methyl-1,8-naphthyridine

- 16 -

- ethyl 7-ethoxy-4-(2-ethoxy-5-pyridylamino)-1,8-naphthyridine-3-carboxylate
- 3-ethoxy-5-(6-ethoxy-2-pyridylamino)-2-methyl-1,8-naphthyridine
- 5 ethyl 6-ethoxy-4-(6-ethoxy-2-pyridylamino)-7-methyl-1,8-naphthyridine-3-carboxylate
- 6-ethoxy-4-(4-methoxyanilino)-7-methyl-1,8-naphthyridine-3-carbonitrile
- 10 ethyl 4-[4-(carbamoylmethoxy)anilino]-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate
- ethyl 4-(2,4-dihydroxy-5-pyrimidinylamino)-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate
- 2-methyl-5-[2-(pyrid-3-yloxy)pyrid-5-ylamino]-1,8-naphthyridine
- 15 ethyl 6-ethoxy-7-methyl-4-(2-phenoxy-5-pyridylamino)-1,8-naphthyridine-3-carboxylate
- ethyl 4-(6-ethoxy-3-ethoxycarbonyl-7-methyl-1,8-naphthyridin-4-ylamino)phenoxyacetate
- 20 ethyl 5-(6-ethoxy-3-ethoxycarbonyl-7-methyl-1,8-naphthyridin-4-ylamino)salicylate
- 3-O-[4-(6-ethoxy-3-ethoxycarbonyl-7-methyl-1,8-naphthyridin-4-ylamino)phenyl]-1,2-O-isopropylidene-glucofuranose
- 25 ethyl 6-ethoxy-4-[4-(β -D-galactopyranosyl)anilino]-7-methyl-1,8-naphthyridine-3-carboxylate
- 4-(6-ethoxy-7-methyl-1,8-naphthyridin-4-ylamino)phenyl β -D-galactopyranoside
- 30 3-O-[4-(6-ethoxy-7-methyl-1,8-naphthyridin-4-ylamino)phenyl]-1,2:5,6-di-O-isopropylidene-D-glucofuranose
- ethyl 6-ethoxy-4-[4-(β -D-lactopyranosyl)anilino]-7-methyl-1,8-naphthyridine-3-carboxylate
- 6-ethoxy-4-[4-(β -D-lactopyranosyl)anilino]-7-methyl-1,8-naphthyridine-3-carboxamide
- 35 ethyl 4-[4-(β -D-galactopyranosyl)anilino]-7-methyl-6-propoxy-1,8-naphthyridine-3-carboxylate
- 2-methyl-5-[4-(2-pyridyloxy)anilino]-1,8-naphthyridine

- 17 -

ethyl 7-methyl-4[4-(2-pyridyloxy)-anilino]-1,8-naphthyridine-3-carboxylate

ethyl 6-ethoxy-7-methyl-4-[4-(2-pyridyloxy)anilino]-1,8-naphthyridine-3-carboxylate

5 3-ethoxy-2-methyl-5-[4-(2-pyridyloxy)anilino]-1,8-naphthyridine

methyl [4-(6-ethoxy-3-ethoxycarbonyl-7-methyl-1,8-naphthyridin-4-ylamino)phenyl-2,3,4-tri-O-acetyl- β -D-glucopyranosid]uronate

10 ethyl 4-(4-hydroxyanilino)-6-methoxy-1,5-naphthyridine-3-carboxylate

4-(6-methoxy-2-methyl-1,5-naphthyridin-4-ylamino)-2-methylphenol

15 4-[4-(2-butoxy)anilino]-6-methoxy-2-methyl-1,5-naphthyridine

and pharmaceutically acceptable salts thereof, in the form of individual enantiomers, racemates or other mixtures of enantiomers.

When a compound of formula I contains a single chiral centre it may exist in two enantiomeric forms. The present invention includes individual enantiomers and mixtures of those enantiomers. The enantiomers may be obtained by methods known to those skilled in the art. Such methods typically include resolution via formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; resolution via formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer by reaction with an enantiomer-specific reagent, for example, enzymatic esterification, oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid

- 18 -

chromatography in a chiral environment, for example on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is
5 converted into another chemical entity by one of the separation processes described above, a further step will subsequently be required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using
10 optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.

When a compound of formula I contains more than one chiral centre it may exist in diastereoisomeric forms.
15 The diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example, chromatography or crystallisation and the individual enantiomers within each pair may be separated as described above. The present invention includes each
20 diastereoisomer of compounds of formula I or II and mixtures thereof.

Certain compounds of formula I may exist in different tautomeric forms which fall within the scope of the present invention.

25 Some compounds of formula I may exist in the form of solvates, for example, hydrates, which also fall within the scope of the present invention.

The compounds of formula I may form organic or inorganic salts, for example, the compounds of formula I
30 may form acid addition salts with inorganic or organic acids, e.g. hydrochloric acid, hydrobromic acid, fumaric acid, tartaric acid, citric acid, sulphuric acid, hydriodic acid, maleic acid, acetic acid, succinic acid, benzoic acid, pamoic acid, palmitic acid, dodecanoic

- 19 -

acid and acidic amino acids such as glutamic acid. Some compounds of formula I may form base addition salts, for example, with alkali metals for example sodium hydroxide, or with aminoacids for example, lysine or 5 arginine. It will be appreciated that such salts, provided they are pharmaceutically acceptable may be used in therapy in place of the corresponding compounds of formula I. Such salts are prepared by reacting the compound of formula I with a suitable acid or base in a 10 conventional manner. Such salts may also exist in form of solvates (for example, hydrates).

Certain compounds of formula I may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof.

15 The present invention also provides pharmaceutical compositions containing a therapeutically effective amount of a compound of formula I (including the compounds of the second proviso) together with a pharmaceutically acceptable diluent or carrier. Such 20 pharmaceutical formulations may be used in the treatment of rheumatic diseases for example rheumatoid arthritis or osteoarthritis.

As used hereinafter, the term "active compound" denotes a compound of formula I. In therapeutic use, 25 the active compound may be administered orally, rectally, parenterally, topically, ocularly, aurally, nasally, intravaginally or to the buccal cavity, to give a local and/or systemic effect. Thus the therapeutic compositions of the present invention may take the form 30 of any of the known pharmaceutical compositions for such methods of administration. The compositions may be formulated in a manner known to those skilled in the art so as to give a controlled release, for example rapid release or sustained release, of the compounds of the 35 present invention. Pharmaceutically acceptable carriers

- 20 -

suitable for use in such compositions are well known in the art of pharmacy. The compositions of the invention may contain 0.1-99% by weight of active compound. The compositions of the invention are generally prepared in 5 unit dosage form. Preferably the unit dosage of active ingredient is 1-500 mg. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art.

10 Compositions for oral administration are preferred compositions of the invention and there are known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oily suspensions.

15 Tablets may be prepared from a mixture of the active compound with fillers such as lactose or calcium phosphate, disintegrating agents, for example maize starch, lubricating agents, for example magnesium stearate, binders for example microcrystalline cellulose or polyvinyl pyrrolidone and other optional ingredients 20 known in the art to permit tabletting the mixture by known methods. The tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate. The tablets may be formulated in a 25 manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate.

30 Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner. The tablets and capsules may 35 conveniently each contain 0.1 to 1000 mg (for example

- 21 -

10 mg, 50 mg, 100 mg, 200 mg, 400 mg or 800 mg) of the active compound. Other compositions for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in 5 the presence of a non-toxic suspending agent such as sodium carboxymethylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example sunflower oil.

The active compound may be formulated into granules 10 with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example water) before ingestion. The granules may contain disintegrants (for example a pharmaceutically acceptable effervescent 15 couple formed from an acid and a carbonate or bicarbonate salt) to facilitate dispersion in the liquid medium.

Compositions for topical administration are also preferred compositions of the invention. The 20 pharmaceutically active compound may be dispersed in a pharmaceutically acceptable cream, ointment or gel. A suitable cream may be prepared by incorporating the active compound in a topical vehicle such as petrolatum and/or light liquid paraffin, dispersed in an aqueous 25 medium using surfactants. An ointment may be prepared by mixing the active compound with a topical vehicle such as a mineral oil, petrolatum and/or a wax e.g. paraffin wax or beeswax. A gel may be prepared by mixing the active compound with a topical vehicle comprising a gelling agent e.g. basified Carbomer BP, in 30 the presence of water. Topically administrable compositions may also comprise a matrix in which the pharmaceutically active compounds of the present invention are dispersed so that the compounds are held 35 in contact with the skin in order to administer the compounds transdermally. A suitable transdermal

- 22 -

composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as described above, together with a potential transdermal accelerant such as dimethyl sulphoxide or
5 propylene glycol.

Compositions of the invention suitable for rectal administration are known pharmaceutical forms for such administration, for example suppositories with hard fat, synthetic glycerides or polyethylene glycol bases.

10 Compositions of the invention suitable for parenteral administration are known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.

15 Compositions of the invention suitable for inhalation via the mouth and/or the nose are the known pharmaceutical forms for such administration, for example aerosols, nebulised solutions or powders. Metered dose systems, known to those skilled in the art, may be used.

20 Compositions suitable for application to the buccal cavity include slow dissolving tablets, troches, chewing gum, gels, pastes, powders, mouthwashes or rinses.

25 The compounds of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion, or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may
30 be a) liquid such as an oily solution or suspension of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or b) solid in the form of an implanted

- 23 -

support for example of a synthetic resin of waxy material for the compound to be infused. The support may be a single body containing all the compound or a series of several bodies each containing part of the
5 compound to be delivered.

In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.

10 In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients, for example, a non-steroidal antiinflammatory agent e.g. ibuprofen, S(+)-ibuprofen, flurbiprofen or S(+)-
15 flurbiprofen, an analgesic or an antipyretic agent.

The compounds of formula I are indicated for use as anti-rheumatic agents by their activity demonstrated by means of tests on standard laboratory animals. Such tests include, for example, the oral administration of
20 compounds of formula I to mice with experimental antigen-induced arthritis. Compounds of formula I are suitable for use in treating rheumatic diseases for example rheumatoid arthritis, osteoarthritis, osteoporosis, crystal arthropathies (e.g. gout),
25 reactive arthritis, ankylosing spondylitis or psoriatic arthropathy.

Compounds of formula I may also be suitable for the treatment of diseases of the oral cavity for example periodontitis, gingivitis and alveolar bone resorption.

30 Accordingly, in a further aspect, the present invention also includes a method of treating rheumatic diseases, particularly rheumatoid arthritis and osteoarthritis, comprising the administration of a

- 24 -

therapeutically effective amount of a compound of formula I (including the compounds of the second proviso) to a mammal in need thereof. Compounds of formula I may also be administered in a prophylactic 5 manner to mammals, particularly humans who have been identified as being susceptible to arthritic diseases. Whilst the precise amount of active compound administered will depend on a number of factors, for example the age of the patient, the severity of the 10 condition and the past medical history and always lies within the sound discretion of the administering physician, a suitable dose for oral administration to mammals, including humans, is generally within the range 0.01-80 mg/kg/ day, more usually 0.2-40 mg/kg/day given 15 in single or divided doses. For parenteral administration, a suitable dose is generally within the range 0.001-80 mg/kg/day, more usually 0.2-40 mg/kg/day given in single or divided doses or by continuous infusion. A suitable preparation for topical 20 administration generally contains the active ingredient within the range 0.01-20% by weight, more usually 0.05-5% by weight. Oral administration is preferred.

The pharmaceutical compositions containing a therapeutically effective amount of a compound of 25 formula I may be used to treat rheumatic diseases such as rheumatoid arthritis and osteoarthritis. In such treatment the amount of the compound of formula I administered per day is in the range 0.1 to 6000 mg.

In yet another aspect, the present invention 30 provides the use of a compound of formula I (including the compounds of the second proviso) in the manufacture of a medicament for use in the treatment of a rheumatic disease such as rheumatoid arthritis and osteoarthritis.

- 25 -

Processes for the preparation of compounds of formula I will now be described. These processes form a further aspect of the present invention.

Compounds of formula I may be converted into other
5 compounds of formula I by functional group modifications known to those skilled in the art. For example, carboxylic acids may be reacted with amines to give amides or with alcohols to give esters.

Compounds of formula I in which R₁ represents a
10 carboxy C₂₋₄ alkyl group may be prepared by reducing a compound of formula I in which R₁ represents a carboxy C₂₋₄ alkenyl group, for example with a reducing agent, e.g. hydrogen in the presence of a catalyst e.g. palladium.

15 Compounds of formula I in which R₁ represents hydroxy may be prepared by hydrolysis of a compound of formula I in which R₁ represents a C₁₋₆ alkoxy group, for example using a base e.g. sodium hydroxide.

Compounds of formula I in which R₄ represents an
20 α-hydroxy C₁₋₆ alkyl group may be prepared by reducing a compound of formula I in which R₄ represents a C₂₋₇ alkoxy carbonyl group or a C₁₋₆ alkanoyl group, by methods known to those skilled in the art, for example using lithium aluminium hydride or lithium
25 triethylborohydride.

Compounds of formula I in which R₂ represents hydroxy may be prepared by reacting a compound of formula I in which R₂ represents a C₁₋₆ alkoxy group with a de-alkylating agent for example aluminium
30 chloride.

Compounds of formula I in which R₄ represents carboxy may be prepared by hydrolysis of compounds of

- 26 -


formula I in which R₄ represents a C₂₋₆ alkoxy carbonyl group by methods known to those skilled in the art, for example using an acid e.g. hydrochloric acid or a base e.g. sodium hydroxide.

5 Compounds of formula I in which R₁ represents an ω-hydroxy C₁₋₆ alkyl may be prepared by reducing a compound of formula I in which R₁ represents a C₂₋₆ alkoxy carbonyl group or a C₂₋₆ alkoxy carbonyl C₁₋₄ alkyl group by methods known to those skilled in the art for
10 example using lithium aluminium hydride or lithium triethylborohydride.

Compounds of formula I in which R₁ represents a carboxyvinyl group may be prepared by reacting compounds of formula I in which R₁ represents methyl with
15 glyoxylic acid for example by heating together optionally in the presence of a catalyst e.g. trifluoroacetic acid.

Compounds of formula I in which R₂ represents a substituted alkanoyloxy compound may be prepared by
20 acylating a compound of formula I in which R₂ represents hydroxy by methods known to those skilled in the art.

Compounds of formula I may be prepared by reacting a compound of formula III



I I I

in which R₂₅ represents a leaving group, including halo,
25 e.g. bromo, chloro, mercapto or methylthio with a compound of formula IV

- 27 -



or a salt thereof by heating, optionally in the presence of an inert organic liquid which is preferably a solvent for the reactants, e.g. an alcohol or an ether, at a temperature in the range 0-150°C, preferably in the 5 range 30-120°C, at atmospheric pressure, optionally in the presence of an acid, for example hydrochloric acid, or a base, for example sodium carbonate or sodium bicarbonate.

Compounds of formula I in which R₁ represents a 10 C₁₋₆ alkoxy group may be prepared by reacting a compound of formula XVII




in which R₂₀ represents a leaving group, for example halo, with an alkali metal C₁₋₆ alkoxide, by heating 15 optionally in the presence of an inert organic liquid which is preferably a solvent for the reactants, for example an alcohol, at a temperature in the range 50-250°C preferably 150-200°C preferably in a sealed vessel under pressure.

Compounds of formula I in which R₁ represents 20 hydroxy may be prepared by displacing R₂₀ from a compound of formula XVII, in which R₂₀ represents a leaving group, for example halo, with a hydroxy group, for example by reacting with an alkali metal hydroxide

- 28 -


in the presence of an inert organic liquid or by hydrolysis using an aqueous acid or base, at a temperature in the range 0-200°C.

Compounds of formula III in which R₂₅ represents
5 halo may be prepared by reacting compounds of formula V



with a halogenating agent for example phosphorus oxychloride or phosphorus oxybromide at a temperature in the range 0-150°C, preferably 20-100°C, optionally in the presence of an inert organic liquid which is 10 preferably a solvent for the reactants. Compounds of formula III in which R₂₅ represents mercapto or methylthio may be prepared from compounds of formula V by methods known to those skilled in the art.


Compounds of formula V in which R₁ represents
15 hydrogen may be prepared by the thermal decarboxylation of compounds of formula VI



for example by heating at a temperature in the range 100-350°C in a suitable organic liquid e.g. diphenyl ether, quinoline or liquid petrolatum.

20 Compounds of formula V in which R₁ represents a substituent other than hydrogen may be prepared by heating compounds of formula VII

- 29 -




VII

in which R₁ represents a substituent other than hydrogen in the presence of a suitable solvent, for example diphenyl ether or liquid petrolatum at a temperature in the range 150 to 350°C.

- 5 Compounds of formula V in which R₄ represents hydrogen may be prepared by heating compounds of formula V in which R₄ represents COOR₁₆ and R₁₆ represents hydrogen or a C₁₋₄ alkyl group, with aqueous sodium hydroxide solution in a sealed vessel or by thermal 10 decarboxylation of compounds of formula V in which R₁₆ represents hydrogen optionally in the presence of an organic liquid, for example quinoline or liquid petrolatum.

Compounds of formula VI may be prepared by
15 oxidising compounds of formula V in which R₁ represents
a C₁₋₆ alkyl group, for example with selenium dioxide,
or by oxidising compounds of formula V in which R₁
represents a carboxyvinyl group for example with
potassium permanganate.

- 20 Compounds of formula VII may be prepared by heating
compounds of formula VIII




- 30 -

in which R₁₇ represents a C₁₋₄ alkyl group in the presence of a suitable solvent, for example diphenyl ether or liquid petrolatum at a temperature in the range 150 to 350°C, or by reacting compounds of formula VIII
5 with phosphorus oxychloride in the presence of polyphosphoric acid.


Compounds of formula VIII, in which R₁ represents a substituent as defined above, other than hydrogen, may be heated in the presence of an organic liquid, for
10 example diphenyl ether or liquid petrolatum at a temperature in the range of 150 to 350°C to produce compounds of formula V.

Compounds of formula VIII in which R₅ represents hydrogen may be prepared by reacting a compound of
15 formula IX




I X

with a compound of formula X



X

in which R₁₇ or R₁₈ independently represent a C₁₋₄ alkyl group or with a compound of formula XI



X I


or a salt thereof, e.g. the sodium salt, in which R₁₇
20 represents a C₁₋₄ alkyl group, in the presence of a suitable solvent, for example ethanol, at a temperature in the range 50 to 200°C.

- 31 -

Compounds of formula VIII in which R₅ represents hydrogen may also be prepared by reacting a compound of formula IX with a tri(C₁₋₄ alkyl)orthoformate and a compound of formula R₄CH₂CO₂R₁₇, for example by heating,
 5 optionally in the presence of a solvent for example acetic anhydride and/or a Lewis acid catalyst for example zinc chloride.

Compounds of formulae IX, X and XI may be prepared by methods known to those skilled in the art.

10 Compounds of formula XII




XII

may be reduced for example, by heating in the presence of reduced iron powder and dilute acid or by hydrogenation in the presence of a catalyst e.g. palladium, to prepare compounds of formula IV, in which
 15 R₉ represents hydrogen.

Compounds of formulae XII, may be prepared by methods known to those skilled in the art.

Compounds of formula XVII may be prepared by reacting a compound of formula XVIII



XVIII

20 in which R₂₁ represents halo, for example chloro or bromo, with a compound of formula IV using conditions analogous to those described for the preparation of compounds of formula I from a compound of formula III and a compound of formula IV.



Compounds of formula XVIII may be prepared by processes analogous to those described for the preparation of compounds of formula III.

5 Certain intermediate compounds of formulae III-X inclusive are believed to be novel compounds. All novel compounds herein form a further aspect of the invention.

10 The therapeutic activity of the compounds of the present invention has been demonstrated by tests which include the oral administration of the compounds to mice with experimental antigen-induced arthritis. The compounds showed activity in the following test:

15 Female BALB/c mice, 8 weeks of age were used: each control group contained either 35, 60 or 80 mice and each test group contained either 13, 15 or 20 mice respectively. The mice were sensitised by subcutaneous injection into the flank with an emulsion (0.1 ml) consisting of a solution of methylated bovine serum albumin (m-BSA) (0.1 mg) in sterile aqueous sodium chloride solution (0.05 ml; 0.15 M) and Complete
20 Adjuvant (0.05 ml) containing, in total, *Mycobacterium* (0.075 mg). Simultaneously each mouse was injected intraperitoneally with an aqueous suspension of heat killed *Bordetella Pertussis* (0.05 ml; 2 x 10⁹ organisms). Identical injections were administered
25 after 7 days. After a further 14 days the left knee-joint of each mouse was injected with a solution of m-BSA (0.1 mg) in aqueous sodium chloride solution (0.01 ml; 0.15 M) (intra-articular challenge). This procedure induced a chronic erosive arthritis restricted to the
30 challenged joint.

- 33 -

The test compounds were suspended in a vehicle of aqueous carboxymethyl cellulose solution (0.25% w/v) containing TWEEN®80 (1.5% w/v) at varying dosages and 0.1 ml was administered to each test mouse by gastric intubation. The control mice received the vehicle with no test compound. Administration occurred daily for 28 days commencing 14 days after intra-articular challenge. After 42 days the test was terminated and the animals were killed using a rising concentration of carbon dioxide and the arthritic hind leg removed.

The femur and tibia were cut midway along their length and the knee-joint trimmed free of skin and musculature. The arthritic joints were placed in perforated plastic holders and fixed in 10% formal saline for at least 48 hours. They were then decalcified in 5% formic acid for 72 hours with constant agitation (replacing the formic acid after the first 24 hours), washed in water, dehydrated in alcohol and embedded in paraffin wax. The joints were sectioned in the sagittal plane at 5 µm and stained with Van Gieson's stain. Each joint was sectioned at two levels.

The severity of arthritis was assessed by examination of the prepared sections. Synovitis and pannus formation were graded on a 0-5 scale, by a skilled operator, according to the degree of synovial lining cell hypertrophy and hyperplasia, infiltration of the synovium by lymphocytes, plasma cells, monocytes/macrophages, fibroblasts and polymorpho-nuclear (PMN) leukocytes and the degree of pannus formation. Erosions of cartilage and bone were also graded on a 0-5 scale, by a skilled operator, the score reflecting the proportion of articular surface eroded as well as the depth of the erosions. Using the combined data the drug effects were expressed as the percentage change in the mean scores for synovitis and erosions

- 34 -

compared to those of the control group. The data were then analysed using the Mann-Whitney U-test.

Those compounds which induced a statistically significant suppression of erosions or synovitis at a 5 dosage of 100 mg/kg or below were deemed to be active. The results obtained are given in the Examples.

As an alternative to histological assessments, analysis of macerated specimens of tibial epiphyses using an image analysis system, may be used to assess 10 the extent of hard tissue erosions. Active compounds are those which significantly reduce these erosions.

The invention is illustrated by the following non-limitative Examples in which parts and percentages are by weight and compositions of mixed solvents are given 15 by volume. Novel compounds were characterised by elemental analysis and one or more of the following spectroscopic techniques: nuclear magnetic resonance, infra-red and mass spectroscopy.

In the Examples the following abbreviations are 20 used: IMS = industrial methylated spirit, DMF = N,N-dimethylformamide and THF = tetrahydrofuran.

Unless otherwise stated, the starting materials used in the Examples were commercially available and may be obtained by reference to the Fine Chemicals 25 Directory.

PREPARATION OF STARTING MATERIALSEXAMPLE A1

- a) 2-Chloro-5-nitropyridine (30.0 g) was added to a solution of sodium metal (4.4 g) in absolute ethanol (250 ml) under a nitrogen atmosphere. The mixture was boiled under reflux for 4 hours, then cooled slightly and filtered. The filtrate was cooled in ice and filtered to give 2-ethoxy-5-nitropyridine, m.p. 85-88°C.
- b) 2-Ethoxy-5-nitropyridine (12.0 g) in IMS (250 ml) was hydrogenated at ambient temperature at atmospheric pressure over 10% palladium charcoal (0.5 g). The catalyst was removed by filtration and the filtrate evaporated to give an oil. The oil was dissolved in ether, filtered and evaporated. A small sample of the oil was dissolved in ether and the solution saturated with hydrogen chloride gas. The mixture was filtered to give 5-amino-2-ethoxypyridine dihydrochloride, m.p. 203-207°C. The remainder of the oil was used in part c) below.
- c) 5-Amino-2-ethoxypyridine (9.25 g) and diethyl ethoxymethylenemalonate (14.5 g) was heated at 95°C for 1 hour. On cooling in ice the oil solidified. The solid was ground up in petroleum ether (b.p. 60-80°C) and filtered to give diethyl 2-(6-ethoxy-3-pyridylaminomethylene)malonate, m.p. 68-71°C.
- d) The malonate from c) above (16.4 g) was added to diphenyl ether (100 ml) at 250°C with stirring over 5 minutes. Heating was continued for a further 10 minutes and then the mixture was cooled to ambient temperature. Petroleum ether b.p. 60-80°C (100 ml) was added and the product was collected by filtration to give ethyl 6-ethoxy-4-hydroxy-1,5-naphthyridine-3-carboxylate, m.p. 275-278°C.

- 36 -

EXAMPLE A2

Ethyl 4-hydroxy-6-methoxy-1,5-naphthyridine-3-carboxylate was prepared in a similar manner to that described in Example A1.

5 EXAMPLE A3

a) 2-Chloro-5-nitropyridine (4.48 g) was added in portions to a mixture of sodium phenoxide trihydrate (4.80 g) in DMF (140 ml) with stirring at ambient temperature under nitrogen. The mixture was then heated 10 at 60°C for 2 hours and then at 90°C for 3 hours. The mixture was allowed to cool over 18 hours. The mixture was poured into ice water and extracted with dichloromethane to give a residue which was stirred in petroleum ether, b.p. 60-80°C at ambient temperature for 15 30 minutes and then filtered to give 5-nitro-2-phenoxyppyridine, m.p. 84-86°C.

b) The product from Part a) (14.9 g) was hydrogenated at ambient temperature in IMS (300 ml) using 10% palladium charcoal (0.5 g) as a catalyst. The catalyst 20 was removed by filtration and the filtrate evaporated to give an oil which solidified on standing. A small sample (1.03 g) was dissolved in ether (50 ml) and the solution filtered to remove a small amount of insoluble material. The filtrate was saturated with hydrogen 25 chloride gas and then filtered to give 5-amino-2-phenoxyppyridine hydrochloride, m.p. 192-195°C.

c) A mixture of 5-amino-2-phenoxyppyridine (10.49 g) and diethyl ethoxymethylenemalonate (12.2 g) was boiled under reflux for 2.5 hours. The mixture was cooled to 30 ambient temperature and water (50 ml) was added. The mixture was extracted with dichloromethane to give diethyl 2-(6-phenoxy-3-pyridylaminomethylene)malonate as an oil.

- 37 -

d) A solution of the malonate from Part c (18.8 g) in ethanol (25 ml) was added to diphenyl ether (100 ml) at 250-260°C over 30 minutes with stirring while allowing the ethanol formed to distil off. The mixture was
5 boiled for 10 minutes after the addition and then cooled to ambient temperature. Petroleum ether, b.p. 60-80°C (100 ml) was added. The mixture was filtered to give ethyl 4-hydroxy-6-phenoxy-1,5-naphthyridine-3-carboxylate, m.p. 254-7°C (dec).

10 EXAMPLE A4

a) Diethyl methylmalonate (52.2 g) was added dropwise to a suspension of sodamide (11.7 g) in dry THF (150 ml) with stirring at ambient temperature under nitrogen. The mixture was boiled under reflux for 1 hour and then
15 a solution of 2-chloro-5-nitropyridine (47.7 g) in dry THF (150 ml) was added dropwise cautiously with stirring. After the addition the mixture was boiled under reflux for 3 hours, then cooled and evaporated to remove approximately 80% of the solvent. The residue
20 was poured into water (1 l) and extracted with ether to give an oil which partially crystallised on standing. A mixture of the residue, concentrated sulphuric acid (50 ml) and water (25 ml) was boiled under reflux for 4 hours then cooled in ice and neutralised using
25 concentrated aqueous sodium hydroxide solution. The mixture was left to stand at ambient temperature for 64 hours and then filtered to give a solid which was extracted continuously with dichloromethane in a soxhlet extractor. The dichloromethane was cooled, dried and
30 evaporated. The residue was filtered and the filtrate was distilled under vacuum to give 2-ethyl-5-nitropyridine, b.p. 82-92°C at 1 mm Hg.

b) 2-Ethyl-5-nitropyridine (16.3 g) was dissolved in IMS (200 ml) and hydrogenated at ambient temperature at
35 1 atmosphere using 10% palladium charcoal (0.5 g) as the

- 38 -

catalyst. The mixture was filtered to remove the catalyst and the filtrate evaporated to give 5-amino-2-ethylpyridine as an oil.

5 c) A mixture of 5-amino-2-ethylpyridine (17.6 g) and diethyl ethoxymethylenemalonate (23.25 g) was heated on a steam bath for 2.5 hours. The mixture was cooled in ice. The solid formed was ground up in petroleum ether,

b.p. 60-80°C and then filtered to give diethyl 2-(6-ethyl-3-pyridylaminomethylene)malonate, m.p. 55-57°C.

10 d) The malonate (17.6 g) from c) was added in portions over 5 minutes to boiling diphenyl ether (100 ml) at 250-260°C, with stirring, while allowing any ethanol formed to distil off. Heating was continued for 10 minutes after the addition and then the mixture was

15 cooled. The mixture was diluted with petroleum ether, b.p. 60-80°C (125 ml) and filtered to give ethyl 6-ethyl-4-hydroxy-1,5-naphthyridine-3-carboxylate, m.p. 262-264°C. (The compound contained approximately 20% of the isomeric 1,7-naphthyridine but was used

20 without further purification).

EXAMPLE A5

Ethyl 3-ethoxy-8-hydroxypyrido[2,3-b]pyrazine-7-carboxylate was prepared as described in Chem. Pharm. Bull. 1974, 22 (8), 1864.

25 EXAMPLE A6

a) Sodium metal (46.2 g) was dissolved in absolute ethanol (1 l) with stirring under nitrogen. 3-Hydroxy-2-methylpyridine (200 g prepared as described in C.A. 48, P4597 h) was added. The mixture was stirred at 30 ambient temperature for 30 minutes and then a solution

- 39 -

- of bromoethane (150 ml) in absolute ethanol (100 ml) was added. The mixture was boiled under reflux for 5 hours then cooled and filtered. The filtrate was evaporated and the residue partitioned between dichloromethane and 5 water. The organic layer was separated off and the aqueous layer extracted with dichloromethane. The combined organic extracts were dried and evaporated. The residue was distilled to give 3-ethoxy-2-methylpyridine b.p. 80-84°C (20 mmHg).
- 10 b) 3-Ethoxy-2-methylpyridine (132.5 g) was added dropwise to concentrated sulphuric acid (530 ml) with stirring and cooling to keep the mixture below 10°C. A mixture of concentrated nitric acid (81 ml) and concentrated sulphuric acid (97 ml) was added dropwise 15 over 4 hours, keeping the temperature below 5°C. The reaction mixture was allowed to warm up slowly to ambient temperature and then added in portions to ice/water (2.5 l). The solid was collected by filtration, washed with water and dried under vacuum at 20 50°C to give 3-ethoxy-2-methyl-6-nitropyridine, m.p. 82-84°C.
- c) The nitropyridine above (176 g), IMS (1.6 l), reduced iron powder (179 g) and water (350 ml) were boiled under reflux. Heating was discontinued while 25 concentrated hydrochloric acid (67 ml) was carefully added dropwise over 20 minutes. The mixture was boiled under reflux for 1.75 hours then cooled and filtered through a filtration aid. The filtrate was evaporated under reduced pressure. Water was added to the residue 30 and the mixture basified with 5M sodium hydroxide. Extractive work-up (dichloromethane) gave 5-ethoxy-6-methylpyridin-2-amine, m.p. 93-96°C.
- d) A mixture of the amine from c) above (138 g) and diethyl ethoxymethylenemalonate (196 g) in IMS (190 ml) 35 was boiled under reflux for 3 hours. The mixture was

- 40 -

cooled and filtered to give diethyl 2-(5-ethoxy-6-methylpyrid-2-ylaminomethylene)malonate, m.p. 132-138°C.

- e) The malonate (118.3 g) from d) above was added to boiling diphenyl ether (1.5 l) over 10 minutes with
5 stirring while allowing the ethanol formed to be removed by downward distillation. The mixture was boiled under reflux for 1.5 hours then cooled and diluted with petroleum ether b.p. 60-80°C (1.5 l). The solid was collected by filtration and washed with petroleum ether
10 b.p. 60-80°C to give ethyl 6-ethoxy-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylate, m.p. 255-258°C.
- f) A mixture of ethyl 6-ethoxy-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylate (7.5 g), sodium hydroxide pellets (1.2 g) and water (20 ml) was heated at 180°C
15 with stirring in a sealed reaction vessel for 16 hours. The mixture was cooled to ambient temperature, filtered and the residue washed with water to give, after drying, 6-ethoxy-7-methyl-1,8-naphthyridin-4-ol, m.p. 278-282°C (with decomposition).

20 EXAMPLE A7

- a) A mixture of 6-ethoxypyridin-2-amine (8.0 g) and diethyl ethoxymethylenemalonate (12.5 g) was heated at 95°C under vacuum for 3 hours and then heated at 95°C at atmospheric pressure for 18 hours. The mixture was
25 cooled to ambient temperature, diluted with petroleum ether b.p. 40-60°C and filtered to give diethyl (6-ethoxy-2-pyridylamino)methylenemalonate, m.p. 58-60°C.
- b) The malonate from a) (15.3 g) was dissolved in diphenyl ether (50 ml) and added dropwise to boiling
30 diphenyl ether (75 ml). The mixture was boiled under reflux for 45 minutes, then cooled and diluted with petroleum ether b.p. 60-80°C. The mixture was filtered

- 41 -

to give ethyl 7-ethoxy-4-hydroxy-1,8-naphthyridine-3-carboxylate, m.p. 175-179°C.

EXAMPLE A8

5 Ethyl 4-hydroxy-7-methyl-6-propoxy-1,8-naphthyridine-3-carboxylate, m.p. 231-235°C was prepared from 3-hydroxy-2-methylpyridine in a similar manner to Example 6e.

EXAMPLE A9

10 Ethyl 4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylate was prepared as described in Aust. J. Chem., 1984, 1065.

EXAMPLE B1

15 Ethyl 6-ethoxy-4-hydroxy-1,5-naphthyridine-3-carboxylate (3.0 g) was added to phosphorus oxychloride (25 ml), with stirring, at ambient temperature. The mixture was heated at 50°C for 45 minutes. The mixture was cooled to 10°C and added to ice/water at less than 5°C. The mixture was then basified with concentrated aqueous ammonia solution SG 0.88 at less than 5°C. The 20 mixture was extracted with dichloromethane to give ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate, m.p. 61-64°C.

EXAMPLE B2

25 A mixture of ethyl 4-hydroxy-6-methoxy-1,5-naphthyridine-3-carboxylate (2.48 g) and phosphorus oxychloride (25 ml) was stirred and heated at 50-55°C for 30 minutes. The mixture was worked up as described in Example B1 to give ethyl 4-chloro-6-methoxy-1,5-naphthyridine-3-carboxylate, m.p. 98-100°C.

- 42 -

EXAMPLE B3

A mixture of ethyl 4-hydroxy-6-phenoxy-1,5-naphthyridine-3-carboxylate (3.0 g) and phosphorus oxychloride (25 ml) was heated at 50°C for 1 hour and
5 then worked up as described in Example B1 to give ethyl 4-chloro-6-phenoxy-1,5-naphthyridine-3-carboxylate, m.p. 133-137°C.

EXAMPLE B4

A mixture of ethyl 6-ethyl-4-hydroxy-1,5-naphthyridine-3-carboxylate (3.0 g) and phosphorus oxychloride (25 ml) was stirred and heated at 40-50°C for 1 hour. The mixture was then cooled and then worked up as described in Example B1 to give ethyl 4-chloro-6-ethyl-1,5-naphthyridine-3-carboxylate, m.p. 94-96°C.
10

15. EXAMPLE B5

Ethyl 3-ethoxy-8-hydroxypyrido[2,3-b]pyrazine-7-carboxylate (2.5 g) was added to a stirred solution of phosphorus oxychloride (50 ml) with stirring. The mixture was heated at 50°C for 3 hours and then worked
20 up as described in Example B1 to give ethyl 8-chloro-3-ethoxypyrido[2,3-b]pyrazine-7-carboxylate which was used directly.

EXAMPLE B6

Ethyl 6-ethoxy-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylate (2.5 g) was added to phosphorus oxychloride (20 ml) with stirring at ambient temperature. The mixture was warmed to 40°C and kept at this temperature for 1 hour then cooled to 10°C. The mixture was added to excess ice/water and the mixture
30 basified with aqueous ammonia solution (specific gravity 0.88) while keeping the temperature below 5°C. The

- 43 -

product was extracted into dichloromethane. The combined dichloromethane extracts were evaporated under reduced pressure at ambient temperature to give ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate, m.p. >250°C.

EXAMPLE B7

In a similar manner to Example B1, 6-ethoxy-7-methyl-1,8-naphthyridin-4-ol (2.15 g) and phosphorus oxychloride (25 ml) were heated at 60°C for 1 hour to give 5-chloro-3-ethoxy-2-methyl-1,8-naphthyridine, m.p. 164°C.

EXAMPLE B8

In a similar manner to Example B1, ethyl 7-ethoxy-4-hydroxy-1,8-naphthyridine-3-carboxylate (8.8 g) and phosphorus oxychloride (50 ml) were heated at 80°C for 25 minutes to give ethyl 4-chloro-7-ethoxy-1,8-naphthyridine-3-carboxylate, m.p. 72-75°C.

EXAMPLE B9

a) A mixture of ethyl 6-ethoxy-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylate (5.0 g) and ethanol saturated with ammonia (80 ml) was stirred and heated in a sealed vessel at 210°C (external temperature) for 20 hours. The mixture was cooled and filtered to give a solid. The filtrate was evaporated under reduced pressure and the residue was washed with ether, then water, to give a second crop of solid. ¹H nmr showed that both crops contained 6-ethoxy-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide along with some starting material. The two crops were combined and used in b).

- 44 -

b) The combined solids from a) were added to phosphorus oxychloride (40 ml) at ambient temperature with stirring. The mixture was then heated on a steam bath with stirring for 1.5 hours and then cooled to 5 10°C. The mixture was then worked up as described in Example B1 to give 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carbonitrile which contained some ester but was used without further purification.

EXAMPLE B10

10 Ethyl 4-chloro-7-methyl-6-propoxy-1,8-naphthyridine-3-carboxylate, m.p. 100-106°C was prepared in a similar manner to Example B6, starting from the product of Example A8.

EXAMPLE B11

15 5-Chloro-2-methyl-1,8-naphthyridine was prepared as described in Aust. J. Chem., 1984, 37, 1065.

EXAMPLE B12

a) A mixture of ethyl 6-ethoxy-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylate (10.0 g), 5M sodium 20 hydroxide solution (200 ml), IMS (64 ml) and water (64 ml) was boiled under reflux for 2 hours. The mixture was cooled to ambient temperature and then filtered. The residue was dissolved in water, acidified to pH5 with glacial acetic acid and filtered. The 25 residue was triturated with hot IMS, cooled and filtered to give 6-ethoxy-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid, m.p. 259-261°C.

b) 6-Ethoxy-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid (8.7 g) was added with stirring to 30 phosphorus oxychloride (75 ml) at ambient temperature. The mixture was heated at 60°C (internal temperature)

- 45 -

for 45 minutes and then cooled to 10°C. The mixture was added dropwise to aqueous ammonia solution (specific gravity 0.88) at 10°C over 4 hours. The mixture was filtered and the solid obtained was washed with absolute 5 ethanol (7 x 100 ml). The combined washings were evaporated under reduced pressure to give 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxamide, which was used without further purification.

EXAMPLE B13

10 Ethyl 4-chloro-7-methyl-1,8-naphthyridine-3-carboxylate, m.p. 89-90°C, was prepared from the product of Example A9 in an analogous manner to Example B6.

EXAMPLE C1

a) 4-Nitrophenoxyacetic acid (10.2 g) was added to 15 thionyl chloride (50 ml) and the mixture was boiled under reflux for 1.5 hours. Excess thionyl chloride was distilled off and the residue was heated with toluene (2 x 50 ml) and the toluene removed by distillation to leave an oil which solidified on cooling. The acid 20 chloride was added in portions to a stirred mixture of absolute ethanol (50 ml) and concentrated aqueous ammonia (50 ml, SG 0.880) at 10-15°C. The mixture was stirred for 45 minutes at 10-15°C and then allowed to warm up to ambient temperature. The mixture was 25 filtered to give 4-nitrophenoxyacetamide, m.p. 153-155°C.

b) The product from a) (8.3 g) was suspended in IMS (250 ml) and hydrogenated at ambient temperature at 1 atmosphere using 10% palladium charcoal (0.5 g) as 30 catalyst. The catalyst was removed by filtration and the filtrate was evaporated to dryness. The residue was triturated with petroleum ether, b.p. 60-80°C and

- 46 -

filtered to give 4-aminophenoxyacetamide, m.p. 123-125°C.

EXAMPLE C2

A mixture of 5-aminosalicylic acid (15 g), absolute 5 ethanol (250 ml) and concentrated sulphuric acid (7.5 ml) was boiled under reflux with stirring for 8.5 hours. The reaction mixture was evaporated to dryness. Water (20 ml) was added to the residue and the mixture filtered. The filtrate was basified with 10 saturated bicarbonate solution and the solid collected by filtration. The solid was extracted into dichloromethane and the extract evaporated to dryness. The residue was triturated with petroleum ether b.p. 40-60°C and filtered to give ethyl 5- 15 aminosalicylate, m.p. 44°C.

EXAMPLE C3

4-Aminophenol (27.3 g) in DMF (200 ml) was added dropwise over 30 minutes to a stirred suspension of sodium hydride (10.0 g, 60% dispersion in mineral oil) 20 in DMF (200 ml) with stirring under nitrogen. When the evolution of hydrogen had ceased, 2-bromopyridine (39.5 g) was added and the resultant solution was heated at 120°C for 6 hours. The DMF was removed under reduced pressure, the residue was dissolved in water (250 ml) 25 and the mixture extracted with dichloromethane. The combined organic extracts were washed with water, 1 M sodium hydroxide solution and then again with water and then with 2 M hydrochloric acid. The acid extracts were basified and extracted with dichloromethane to give an 30 oil which solidified on standing. This solid was triturated in petroleum ether, b.p. 40-60°C/ethyl acetate (10:1) to give 4-(2-pyridyloxy)aniline, m.p. 64-67°C.

- 47 -

EXAMPLE C4

- a) Sodium hydride (1.53 g, 60% dispersion in mineral oil) was added in portions to a solution of 1,2:5,6-di-O-isopropylidene-D-glucofuranose (10.0 g) in DMF (40 ml) 5 and toluene (80 ml) with stirring under nitrogen. The mixture was boiled under reflux for 15 minutes then cooled and 4-fluoronitrobenzene (5.4 g) was added. The resulting solution was boiled under reflux for 5 hours. The mixture was cooled and washed with water. The 10 organic phase was separated, dried and evaporated under reduced pressure. The residue was recrystallised from IMS to give 1,2:5,6-di-O-isopropylidene-3-O-(4-nitrophenyl)-D-glucofuranose, m.p. 122-126°C.
- b) The product from Part 1 (5.0 g) was hydrogenated in 15 absolute ethanol (300 ml) in the presence of 10% palladium on charcoal (150 mg) at atmospheric pressure. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under reduced pressure to give 3-O-(4-aminophenyl)-1,2:5,6-di-O-isopropylidene- 20 D-glucofuranose which was used without further purification.

Preparation of Examples of the Invention

EXAMPLE 1

- A mixture of ethyl 4-chloro-6-ethoxy-1,5- 25 naphthyridine-3-carboxylate (3.1 g), 4-methoxyaniline (1.36 g) and IMS (40 ml) was boiled under reflux for 4 hours. The mixture was evaporated to dryness. The residual solid was ground in ether and then filtered. The solid was dissolved in dichloromethane and purified 30 by column chromatography on silica using dichloromethane, then ether, then ethyl acetate, then IMS, as the mobile phase. The third fraction obtained was dissolved in IMS (30 ml) and the solution was saturated with hydrogen chloride gas. Ether was added

- 48 -

and the mixture left to stand at approximately 4°C for 3 days. The mixture was filtered to give ethyl 6-ethoxy-4-(4-methoxyanilino)-1,5-naphthyridine-3-carboxylate hydrochloride hydrate, m.p. 130-133°C.

5 Active (3/3) at 30 mg/kg.

EXAMPLE 2

A mixture of ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate (17.95 g), 4-methoxyaniline (8.29 g), anhydrous potassium carbonate (18.6 g) and THF (250 ml) was stirred at ambient temperature for 48 hours. The mixture was evaporated to dryness and water was added to the residue. The mixture was extracted with dichloromethane to give a solid which was dissolved in IMS (50 ml). The solution was saturated with hydrogen chloride gas whilst cooling the mixture in ice. Ether was added to induce precipitation. The solid was collected by filtration to give ethyl 6-ethoxy-4-(4-methoxyanilino)-1,5-naphthyridine-3-carboxylate hydrochloride, m.p. 160-162°C.

20 Active (3/3) at 30 mg/kg.

EXAMPLE 3

A mixture of ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate (2.41 g), 4-(2-diethylamino)ethoxyaniline (2.04 g), anhydrous potassium carbonate (2.49 g) and THF (70 ml) was stirred at ambient temperature for 72 hours. The mixture was filtered and the filtrate evaporated to give an oil which solidified on standing. The solid was ground in ether and filtered. The filtrate was evaporated and the residue purified by chromatography on silica using ethyl acetate as a mobile phase to remove impurities followed by dichloromethane:IMS (9:1) as a mobile phase to elute the product. The product was obtained as an oil which was dissolved in IMS (25 ml). The solution was

- 49 -

saturated with hydrogen chloride gas with cooling. Ether was added to induce crystallisation. The solid was collected by filtration to give ethyl 6-ethoxy-4-[4-(2-diethylaminoethoxy)anilino]-1,5-naphthyridine-3-carboxylate dihydrochloride, m.p. 188-189°C.

EXAMPLE 4

A mixture of ethyl 4-chloro-6-methoxy-1,5-naphthyridine-3-carboxylate (1.68 g), 4-methoxyaniline (0.78 g), dry THF (50 ml) and anhydrous potassium carbonate (1.74 g) was stirred at ambient temperature for 7 hours. Further amounts of 4-methoxyaniline (0.4 g) and anhydrous potassium carbonate (0.9 g) were added and the mixture stirred at ambient temperature for 32 hours. The mixture was evaporated to dryness and the residue diluted with water (100 ml). The mixture was extracted into dichloromethane to give an oil which solidified. The solid was purified by column chromatography on silica using ethyl acetate as the mobile phase to give ethyl 6-methoxy-4-(4-methoxyanilino)-1,5-naphthyridine-3-carboxylate, m.p. 115-117°C.

EXAMPLE 5

A mixture of ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate (3.30 g) 4-(2-pyridyloxy)-aniline (2.25 g), anhydrous potassium carbonate (3.43 g) and THF (90 ml) was stirred at ambient temperature for 72 hours. The mixture was filtered and the filtrate evaporated to dryness to give a residue which was dissolved in IMS (50 ml). This solution was saturated with hydrogen chloride gas with cooling in ice. The mixture was filtered and the solid collected was discarded. The filtrate was cooled in ice and diluted with ether. The mixture was filtered and the solid which was collected was dissolved in warm IMS and

- 50 -

reprecipitated with ether. The mixture was again filtered and the filtrate was evaporated to dryness. The residue was purified by flash chromatography on silica using dichloromethane:IMS (19:1) as the mobile 5 phase. The solid obtained was recrystallised from IMS to give ethyl 6-ethoxy-4-[4-(2-pyridyloxy)anilino]-1,5-naphthyridine-3-carboxylate, m.p. 148-151°C.
Active (1/1) at 30 mg/kg.

EXAMPLE 6

10 A mixture of ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate (2.1 g), 2-ethoxy-5-aminopyridine (1.08 g), anhydrous potassium carbonate (2.17 g) and THF (60 ml) was stirred at ambient temperature for 48 hours. The mixture was evaporated to 15 dryness and water added to the residue. The mixture was extracted with dichloromethane to give an oily solid. This solid was dissolved in IMS (20 ml) and the solution saturated with hydrogen chloride gas while cooling in ice. Ether was added to induce precipitation. The 20 mixture was filtered to give ethyl 6-ethoxy-4-(2-ethoxy-5-pyridylamino)-1,5-naphthyridine-3-carboxylate hydrochloride, m.p. 187-189°C.
Borderline active (1/1) at 30 mg/kg.

EXAMPLE 7

25 A mixture of ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate (2.4 g), 4-(2-hydroxyethoxy)aniline (1.4 g), anhydrous potassium carbonate (2.49 g) and THF (70 ml) was stirred at ambient temperature for 3 days. The mixture was 30 filtered and the filtrate evaporated to dryness. The residue was ground up in ether and filtered. The residue was dissolved in dichloromethane and purified by chromatography on silica. The product fractions were combined, dissolved in IMS (150 ml) and saturated with

- 51 -

hydrogen chloride gas. The mixture was cooled in ice and diluted with ether to induce precipitation. The mixture was filtered to give ethyl 6-ethoxy-4-[4-(2-hydroxyethoxy)anilino]-1,5-naphthyridine-3-carboxylate hydrochloride, m.p. 177-178°C.

EXAMPLE 8

A mixture of ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate (0.86 g), 4-aminophenyl- β -D-galactopyranoside (0.84 g) and IMS (30 ml) was boiled under reflux for 1 hour. The mixture was cooled in ice and then filtered to give ethyl 6-ethoxy-4-[4-(β -D-galactopyranosyl)anilino]-1,5-naphthyridine-3-carboxylate hemihydrochloride, m.p. 189-191°C.

EXAMPLE 9

15 A mixture of ethyl 4-chloro-6-phenoxy-1,5-naphthyridine-3-carboxylate (3.0 g), 4-methoxyaniline (1.16 g), potassium carbonate (2.65 g) and THF (60 ml) was stirred at ambient temperature for 24 hours. The reaction mixture was worked up as described in Example 2
20 to give ethyl 4-(4-methoxyanilino)-6-phenoxy-1,5-naphthyridine-3-carboxylate hydrochloride, m.p. 191-193°C.

EXAMPLE 10

A mixture of 4,7-dichloro-1,5-naphthyridine (0.65 g), 4-methoxyaniline (0.40 g) and IMS (25 ml) was boiled under reflux for 5 hours. The mixture was concentrated to approximately 5 ml and then ether added to induce precipitation. Ethyl acetate was added and the solid was collected by filtration to give 7-chloro-30 4-(4-methoxyanilino)-1,5-naphthyridine hydrochloride hydrate m.p. 230-233°C.

- 52 -

EXAMPLE 11

A mixture of ethyl 4-chloro-6-ethyl-1,5-naphthyridine-3-carboxylate (2.1 g), 4-methoxyaniline (1.0 g) and IMS (50 ml) was boiled under reflux for 5 2.5 hours. The mixture was evaporated under reduced pressure to give an oil which was purified by flash column chromatography on silica using dichloromethane/IMS, 19:1 as the mobile phase to give the product as an oil which was dissolved in methanol 10 (15 ml). This solution was saturated with hydrogen chloride gas and then diluted with ether, with cooling. The solid was collected by filtration to give ethyl 6-ethyl-4-(4-methoxyanilino)-1,5-naphthyridine-3-carboxylate, m.p. 145-148°C.

15 EXAMPLE 12

A mixture of ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate (2.0 g), absolute ethanol (30 ml) and 4-(2,3-dihydroxypropoxy)aniline (1.38 g) was boiled under reflux for 1 hour. The reaction mixture 20 was hot filtered and the filtrate evaporated to dryness. The residue was triturated with dichloromethane and filtered. The filtrate was evaporated to dryness and the residue was purified by column chromatography on silica using ethyl acetate as the mobile phase to give 25 ethyl 6-ethoxy-4-[4-(2,3-dihydroxypropoxy)anilino]-1,5-naphthyridine-3-carboxylate, m.p. 143-145°C.

EXAMPLE 13

A mixture of ethyl 8-chloro-3-ethoxypyrido[2,3-b]-pyrazine-7-carboxylate (2.32 g) and 4-methoxyaniline 30 (1.0 g) in ethanol (40 ml) was boiled under reflux for 1 hour. The mixture was allowed to cool and the solvent removed under reduced pressure. The residue was triturated with hot ethyl acetate and filtered to give a

- 53 -

solid which was recrystallised from ethyl acetate to give a solid which was purified by chromatography on silica to give ethyl 3-ethoxy-8-(4-methoxyanilino)-pyrido[2,3-b]pyrazine-7-carboxylate sesquihydrochloride 5 hydrate, m.p. 143-145°C.

EXAMPLE 14

A mixture of ethyl 4-chloro-6-ethoxy-1,5-naphthyridine-3-carboxylate (2.0 g), ethyl 5-aminosalicylate (1.37 g) and absolute alcohol (30 ml) 10 was boiled under reflux for 3 hours and then cooled to ambient temperature. The mixture was filtered to give a solid which was recrystallised from IMS to give ethyl 5-(6-ethoxy-3-ethoxycarbonyl-1,5-naphthyridin-4-ylamino) salicylate hydrochloride, m.p. 204-206°C.

15 EXAMPLE 15

a) The mixture of 5-chloro-3-ethoxy-2-methyl-1,8-naphthyridine (5.0 g), 4-methoxyaniline (2.77 g) and IMS (40 ml) was boiled under reflux for 2.5 hours. The mixture was cooled and filtered. The solid obtained was 20 dissolved in boiling IMS (50 ml) and 5 M sodium hydroxide solution (4.0 ml) was added. The mixture was heated under reflux for 1 hour and then cooled and water (100 ml) was added. The mixture was filtered to give 3-ethoxy-5-(4-methoxyanilino)-2-methyl-1,8-naphthyridine 25 hydrate, m.p. 228-231°C.

b) The product from a) (2.0 g) was suspended in dichloromethane (30 ml) and added to a suspension of anhydrous aluminium chloride (4.3 g) in dichloromethane (37.5 ml) with stirring at ambient temperature. The 30 mixture was stirred for 24 hours, then more aluminium chloride (4.3 g) was added and the mixture stirred for a further 24 hours, then poured into ice water and stirred for 10 minutes. The solid was collected by filtration,

- 54 -

washed well with ether, dried and then recrystallised from IMS to give 3-hydroxy-5-(4-methoxyanilino)-2-methyl-1,8-naphthyridine, m.p. 169-174°C.

- c) Acetoxyacetyl chloride (1.0 ml) was added dropwise
5 to a stirred mixture of the product from b) (2.2 g),
N,N-dimethylaniline (1.0 g) and dichloromethane (75 ml)
at ambient temperature. The mixture was boiled under
reflux for 2 hours and then cooled and filtered. The
product was dissolved in IMS then cooled and
10 precipitated with ether. The product was collected by
filtration, dissolved in IMS, hot filtered and then
precipitated with ether to give 5-(4-methoxyanilino)-2-
methyl-1,8-naphthyridin-3-yl acetoxyacetate,
m.p. 213-216°C.
15 Active (1/1) at 30 mg/kg.

EXAMPLE 16

- a) A mixture of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (3.5 g) and 4-methoxyaniline (1.5 g) in ethanol (50 ml) was boiled under reflux for
20 1.5 hours. The mixture was concentrated to half the volume, cooled and ether added. The solid was collected by filtration to give ethyl 6-ethoxy-4-(4-methoxyanilino)-7-methyl-1,8-naphthyridine-3-carboxylate hydrochloride, m.p. 260-262°C.
- 25 b) A mixture of the product from a) (4.76 g), glyoxylic acid (1.73 g) and glacial acetic acid (50 ml) was boiled under reflux for 24 hours. The mixture was cooled and the solid was collected by filtration. The filtrate was acidified with concentrated hydrochloric acid and filtered to give a second crop of solid. The two crops of solid were combined, stirred in water and the mixture basified with sodium bicarbonate. The pH of the mixture was adjusted to pH 6 with concentrated hydrochloric acid and the mixture was extracted with

- 55 -

ethyl acetate and then with dichloromethane. The combined organic extracts were washed with water, dried and evaporated. The residue was triturated with ethyl acetate and then filtered to give 3-[3-ethoxy-6-
5 ethoxycarbonyl-5-(4-methoxyanilino)-1,8-naphthyridin-2-yl]acrylic acid hemihydrochloride, m.p. 259-261°C.

c) A mixture of the product from b) (4.0 g), triethylamine (1.45 g) and DMF (300 ml) was stirred in an ice bath and treated with ethyl chloroformate (a
10 molar equivalent). The solution was stirred at 0°C for 1 hour and then concentrated aqueous ammonia solution (3 ml, SG 0.88) was added. The mixture was shaken with dichloromethane and aqueous sodium bicarbonate solution. The organic extract was separated, washed with sodium
15 bicarbonate solution, water, dried and evaporated to give a liquid and a solid. This mixture was triturated with ether to give a solid which was purified by chromatography on silica using dichloromethane with gradually increasing amounts of methanol to give a solid
20 which was recrystallised from ethanol/dichloromethane to give ethyl 7-(2-carbamoylvinyl)-6-ethoxy-4-(4-methoxyanilino)-1,8-naphthyridine-3-carboxylate, m.p. 238-242°C.

EXAMPLE 17

25 A mixture of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (2.4 g), 5-amino-2-ethoxypyridine (1.15 g) and IMS (50 ml) was boiled under reflux for 1.5 hours. The mixture was cooled and filtered to give ethyl 6-ethoxy-4-(2-ethoxy-5-
30 pyridylamino)-7-methyl-1,8-naphthyridine-3-carboxylate hydrochloride, m.p. 221-223°C.
Active (1/1) at 30 mg/kg.

- 56 -

EXAMPLE 18

A mixture of 5-chloro-3-ethoxy-2-methyl-1,8-naphthyridine (2.0 g), 5-aminopyridin-2-ol (1.0 g) and IMS (20 ml) was boiled under reflux for 2 hours. The
5 mixture was cooled and filtered to give 5-(3-ethoxy-2-methyl-1,8-naphthyridin-5-ylamino)pyridin-2-ol hydrochloride sesquihydrate, m.p. 295-300°C.

EXAMPLE 19

A mixture of 5-chloro-3-ethoxy-2-methyl-1,8-naphthyridine (2.0 g), 5-amino-2-ethoxypyridine (1.25 g) and IMS (20 ml) was boiled under reflux for 2 hours. The mixture was cooled and filtered to give 3-ethoxy-5-(2-ethoxy-5-pyridylamino)-2-methyl-1,8-naphthyridine hydrochloride dihydrate, m.p. 184-187°C.
15 Active (2/3) at 30 mg/kg.

EXAMPLE 20

A mixture of ethyl 4-chloro-7-ethoxy-1,8-naphthyridine-3-carboxylate (1.6 g) and 5-amino-2-ethoxypyridine (0.8 g) and IMS (50 ml) was boiled under
20 reflux for 2 hours. The mixture was cooled and ether (200 ml) was added. The mixture was filtered to give ethyl 7-ethoxy-4-(2-ethoxy-5-pyridylamino)-1,8-naphthyridine-3-carboxylate hydrochloride, m.p. 180-185°C.
25 Active (1/1) at 30 mg/kg.

EXAMPLE 21

A mixture of 5-chloro-3-ethoxy-2-methyl-1,8-naphthyridine (0.98 g), 6-amino-2-ethoxypyridine (0.6 g), IMS (25 ml) and concentrated hydrochloric acid
30 (2 drops) was boiled under reflux for 18 hours. The

- 57 -

mixture was cooled and filtered to give 3-ethoxy-5-(6-ethoxy-2-pyridylamino)-2-methyl-1,8-naphthyridine hydrochloride, m.p. >250°C.

Active (1/1) at 30 mg/kg.

5 EXAMPLE 22

A mixture of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (1.3 g), 6-amino-2-ethoxy pyridine (0.68 g), IMS (25 ml) and concentrated hydrochloric acid (2 drops) was boiled under reflux for
10 18 hours. The mixture was cooled and filtered to give ethyl 6-ethoxy-4-(6-ethoxy-2-pyridylamino)-7-methyl-1,8-naphthyridine-3-carboxylate sesquihydrochloride hydrate, m.p. 195-200°C.

Active (1/1) at 30 mg/kg.

15 EXAMPLE 23

A mixture of 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carbonitrile (2.66 g), 4-methoxyaniline (1.35 g) and IMS (50 ml) was boiled under reflux for 2.5 hours. The mixture was cooled in ice and the
20 precipitate was collected by filtration. This solid was boiled in IMS (50 ml), with 5 M sodium hydroxide solution (1.2 ml) under reflux for 30 minutes. The mixture was cooled and evaporated. The residue was purified by flash chromatography on silica using
25 dichloromethane/IMS, 19:1 as the mobile phase to give a solid which was ground up in IMS (15 ml) and filtered to give 6-ethoxy-4-(4-methoxyanilino)-7-methyl-1,8-naphthyridine-3-carbonitrile, m.p. 190-192°C.

Active (1/1) at 30 mg/kg.

- 58 -

EXAMPLE 24

A mixture of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (2.0 g), 4-aminophenoxy acetamide (1.13 g) and absolute ethanol (30 ml) was
5 boiled under reflux for 1 hour and then cooled to ambient temperature. The mixture was filtered to give ethyl 4-[4-(carbamoylmethoxy)anilino]-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate hydrochloride, m.p. 215-217°C.

10 EXAMPLE 25

A mixture of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (2.0 g), 5-aminopyrimidine-2,4-diol (0.86 g) and IMS (25 ml) was boiled under reflux for 3 hours. The mixture was concentrated to
15 approximately 15 ml, then cooled at 0°C. The mixture was filtered to give ethyl 4-(2,4-dihydroxy-5-pyrimidinylamino)-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate hemihydrochloride dihydrate, m.p. 250°C.
Active (1/1) at 30 mg/kg.

20 EXAMPLE 26

A mixture of 5-chloro-2-methyl-1,8-naphthyridine (1.8 g), 5-amino-2-(pyrid-3-yloxy)pyridine (1.87 g) and IMS (35 ml) was boiled under reflux for 5 hours. The mixture was cooled to ambient temperature and filtered
25 to give a solid which was recrystallised from IMS to give 2-methyl-5-[2-(pyrid-3-yloxy)pyrid-5-ylamino]-1,8-naphthyridine hydrochloride 2.5 hydrate, m.p. 235-237°C.
Borderline active (1/1) at 30 mg/kg.

- 59 -

EXAMPLE 27

A mixture of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (2.3 g), 5-amino-2-phenoxyypyridine (1.52 g) and IMS (50 ml) was boiled
5 under reflux for 2 hours. The mixture was cooled in ice and filtered to give ethyl 6-ethoxy-7-methyl-4-(2-phenoxy-5-pyridylamino)-1,8-naphthyridine-3-carboxylate hydrochloride, m.p. 220-221°C.

EXAMPLE 28

10 A mixture of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (3.1 g), 4-aminophenoxyacetic acid hydrochloride (2.17 g) (prepared by reduction of 4-nitrophenoxyacetic acid using hydrogen and 10% palladium charcoal in a similar manner to
15 Example C1 followed by treatment with 5 M hydrochloric acid and then evaporation) and absolute ethanol (30 ml) was boiled under reflux for 4 hours. The mixture was cooled to ambient temperature and filtered to give ethyl 4-(6-ethoxy-3-ethoxycarbonyl-7-methyl-1,8-naphthyridin-
20 4-ylamino)phenoxyacetate hydrochloride, m.p. 192-194°C.
Active (1/1) at 30 mg/kg.

EXAMPLE 29

A mixture of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (2.0 g), absolute ethanol (30 ml) and ethyl 5-aminosalicylate (1.23 g) was boiled
25 under reflux for 1 hour. The mixture was cooled to ambient temperature and filtered to give a solid which was recrystallised from IMS to give ethyl 5-(6-ethoxy-3-ethoxycarbonyl-7-methyl-1,8-naphthyridin-4-
30 4-ylamino)salicylate hydrochloride, m.p. 208-210°C.

- 60 -

EXAMPLE 30

A solution of 3-O-(4-aminophenyl)-1,2:5,6-di-O-isopropylidene-D-glucofuranose (2.22 g) in a minimal volume of IMS was added to a solution of ethyl 4-chloro-5 6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (1.87 g) in IMS (40 ml). The mixture was boiled under reflux for 18 hours. The mixture was evaporated to dryness under reduced pressure and the solid residue was recrystallised from ethanol/ether to give 3-O-[4-(6-10 ethoxy-3-ethoxycarbonyl-7-methyl-1,8-naphthyridin-4-ylamino)phenyl]-1,2-O-isopropylidene glucofuranose hydrochloride, m.p. 153-159°C.

EXAMPLE 31

A solution of p-aminophenyl galactopyranoside 15 (1.83 g) in a minimal volume of ethanol was added to a solution of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (2.0 g) in absolute ethanol (40 ml). The mixture was boiled under reflux for 18 hours and then cooled and triturated with ether 20 giving an oil. The supernatant solution was decanted away from the oil and this solution was triturated with more ether to produce a solid which was collected by filtration to give ethyl 6-ethoxy-4-[4-(β -D-galactopyranosyl)anilino]-7-methyl-1,8-naphthyridine-3-25 carboxylate hydrochloride, m.p. 150-153°C.
Active (1/2) at 30 mg/kg.

EXAMPLE 32

A solution of 4-aminophenyl- β -D-galactopyranoside (2.08 g) in IMS (50 ml) was added to a solution of 5-30 chloro-3-ethoxy-2-methyl-1,8-naphthyridine (1.7 g) in IMS (30 ml). The mixture was boiled under reflux for

- 61 -

18 hours. The mixture was cooled and filtered to give 4-(6-ethoxy-7-methyl-1,8-naphthyridin-4-ylamino)phenyl β -D-galactopyranoside hydrochloride, m.p. 223-225°C. Active (1/1) at 30 mg/kg.

5 EXAMPLE 33

A solution of 3-O-(4-aminophenyl-1,2:5,6-di-O-isopropylidene-D-glucofuranose (3.15 g) in a minimal amount of IMS was added to a solution of 5-chloro-3-ethoxy-2-methyl-1,8-naphthyridine (2.0 g) in IMS 10 (40 ml). The mixture was boiled under reflux for 18 hours and then concentrated under reduced pressure to approximately 75% of its original volume. This solution was triturated with ether to induce precipitation. The solid was collected by filtration and recrystallised 15 from IMS/ether to give 3-O-[4-(6-ethoxy-7-methyl-1,8-naphthyridin-4-ylamino)phenyl]-1,2:5,6-di-O-isopropylidene-D-glucofuranose hydrochloride, m.p. 251-254°C.

EXAMPLE 34

20 A suspension of 4-aminophenyl- β -D-lactopyranoside (1.0 g) in IMS (40 ml) was added to a solution of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (0.68 g) in IMS (20 ml). The mixture was boiled under reflux for 18 hours, then cooled and 25 triturated with ether. The solid was collected by filtration to give ethyl 6-ethoxy-4-[4-(β -D-lactopyranosyl)anilino]-7-methyl-1,8-naphthyridine-3-carboxylate hydrochloride dihydrate, m.p. 180-183°C. Active (1/1) at 30 mg/kg.

- 62 -

EXAMPLE 35

A solution of 4-aminophenyl- β -D-lactopyranoside (1.0 g) in a minimal volume of IMS was added to a solution of 4-chloro-6-ethoxy-7-methyl-1,8-5 naphthyridine-3-carboxamide (prepared from the product of Example B9a in an analogous manner to Example B6) (0.61 g) in IMS (40 ml). The mixture was boiled under reflux for 3.5 hours, then cooled and triturated with ether. The solid was collected by filtration to give 6-10 ethoxy-4-[4-(β -D-lactopyranosyl)anilino]-7-methyl-1,8-naphthyridine-3-carboxamide hydrochloride sesquihydrate, m.p. 176-180°C.

EXAMPLE 36

A mixture of ethyl 4-chloro-7-methyl-6-propoxy-1,8-15 naphthyridine-3-carboxylate (1.3 g), 4-aminophenyl- β -D-galactopyranoside (1.17 g) and IMS (40 ml) was boiled under reflux for 4 hours. The mixture was cooled at ambient temperature overnight and then cooled in ice and ether added to induce precipitation. The solid was 20 collected by filtration and dissolved in hot IMS (75 ml), cooled in ice and precipitated with ether. The solid was collected by filtration and the crystallisation process repeated. The solid obtained was purified by chromatography on silica using 25 dichloromethane/IMS, 4:1 as the mobile phase to give ethyl 4-[4-(β -D-galactopyranosyl)anilino]-7-methyl-6-propoxy-1,8-naphthyridine-3-carboxylate hydrochloride sesquihydrate, m.p. 148-52°C (dec).

EXAMPLE 37

30 A mixture of 2-methyl-5-chloro-1,8-naphthyridine (2.0 g), 4-(2-pyridyloxy)aniline (2.1 g) and IMS (50 ml) was boiled under reflux for 3.5 hours. The mixture was

- 63 -

cooled and filtered to give a solid. The solid was suspended in IMS (770 ml) and hydrogen chloride gas was bubbled through the mixture while the mixture was cooled in an ice bath. The mixture was then warmed until all
5 the solid had dissolved and then cooled in an ice bath and further hydrogen chloride gas was bubbled through. After standing at 0°C for 3 minutes, ethyl acetate (approximately 150 ml) was added and the precipitate was collected by filtration to give 2-methyl-5-[4-(2-pyridyloxy)anilino]-1,8-naphthyridine hydrochloride
10 hydrate, m.p. 299-305°C.
Active (1/2) at 30 mg/kg.

EXAMPLE 38

A mixture of ethyl 4-chloro-7-methyl-1,8-naphthyridine-3-carboxylate (2.49 g) and 4-(2-pyridyloxy)aniline (1.85 g) in IMS (50 ml) was boiled under reflux for 1 hour. The mixture was allowed to stand at ambient temperature overnight and then evaporated under reduced pressure. The residue was
15 triturated with ethyl acetate and filtered to give a solid which was recrystallised from ethanol/ethyl acetate. This solid was dissolved in IMS and hydrogen chloride gas was bubbled through the solution with cooling. The solvent was then evaporated under reduced
20 pressure and the residue was recrystallised from ethanol/ethyl acetate to give ethyl 7-methyl-4-[4-(2-pyridyloxy)anilino]-1,8-naphthyridine-3-carboxylate hydrochloride, m.p. 207-208°C.
25 Active (2/2) at 30 mg/kg.

30 EXAMPLE 39

A mixture of 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (1.6 g) and 4-(2-pyridyloxy)aniline (1.0 g) and IMS (50 ml) was boiled under reflux for 1 hour and then allowed to stand at

- 64 -

ambient temperature overnight. The mixture was evaporated under reduced pressure and the residue was recrystallised from ethyl acetate/IMS to give a solid which was dissolved in IMS with warming to give a
5 solution. The solution was cooled in an ice bath and hydrogen chloride gas was bubbled through the mixture. The solid was collected by filtration to give ethyl 6-ethoxy-7-methyl-4-[4-(2-pyridyloxy)anilino]-1,8-naphthyridine-3-carboxylate dihydrochloride,
10 m.p. 223-224°C.

Active (1/1) at 30 mg/kg.

EXAMPLE 40

A mixture of 5-chloro-3-ethoxy-2-methyl-1,8-naphthyridine (2.0 g) and 4-(2-pyridyloxy)aniline (1.67 g) in IMS (50 ml) was boiled under reflux for
15 3 hours and then allowed to stand at ambient temperature overnight. The mixture was evaporated under reduced pressure and the residue recrystallised from IMS to give a solid which was dissolved in hot IMS and then cooled
20 in an ice bath while hydrogen chloride gas was bubbled through. The mixture was evaporated to dryness and the residue was recrystallised from IMS to give 3-ethoxy-2-methyl-5-[4-(2-pyridyloxy)anilino]-1,8-naphthyridine dihydrochloride trihydrate, m.p. 244-247°C.
25 Borderline active (1/1) at 30 mg/kg.

EXAMPLE 41

a) A mixture of methyl p-nitrophenyl 2,3,4-tri-O-acetyl- β -D-glucouronate (2.0 g), ethanol (70 ml) and platinum oxide catalyst (0.125 g) was hydrogenated with
30 stirring under 3 atmospheres of hydrogen. The mixture was filtered and the filtrate concentrated under reduced pressure to give methyl (p-aminophenyl-2,3,4-tri-O-acetyl- β -D-glucopyranosid)-uronate.

- 65 -

b) Methyl (p-aminophenyl-2,3,4-tri-O-acetyl- β -D-glucopyranosid)uronate (1.5 g) in a small volume of IMS was added to a solution of ethyl 4-chloro-6-ethoxy-7-methyl-1,8-naphthyridine-3-carboxylate (1.05 g) in IMS (40 ml). The mixture was boiled under reflux for 18 hours and then cooled to ambient temperature. The mixture was filtered. The filtrate was diluted with ether and then filtered to give methyl [4-(6-ethoxy-3-ethoxycarbonyl-7-methyl-1,8-naphthyridin-4-ylamino)-phenyl-2,3,4-tri-O-acetyl- β -D-glucopyranosid]uronate hydrochloride hemihydrate, m.p. 200-204°C.

The following were prepared by analogous methods to those described in these Examples.

EXAMPLE 42

15 Ethyl 4-(4-hydroxyanilino)-6-methoxy-1,5-naphthyridine-3-carboxylate hydrochloride, m.p. 205-207°C.
Active (1/1) at 30 mg/kg.

EXAMPLE 43

20 4-(6-Methoxy-2-methyl-1,5-naphthyridin-4-ylamino)-2-methylphenol, m.p. 262-264°C.

EXAMPLE 44

4-[4-(2-Butoxy)anilino]-6-methoxy-2-methyl-1,5-naphthyridine hydrochloride hydrate, m.p. 151-153°C.
25 Active (1/2) at 30 mg/kg.

- 66 -

PHARMACEUTICAL EXAMPLES

Example U

In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose 5 are de-aggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing 10 mg active compound.

Example V

Tablets are prepared from the following 10 ingredients.

	<u>Parts by Weight</u>
Active compound	10
Lactose	190
Maize starch	22
15 Polyvinylpyrrolidone	10
Magnesium stearate	3

The active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinylpyrrolidone 20 in ethanol. The dry granulate is blended with magnesium stearate and the rest of the starch. The mixture is then compressed in a tabletting machine to give tablets containing 10 mg of active compound.

Example W

25 Tablets are prepared by the method of the previous Example. The tablets are enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1:1).

- 67 -

Example X

In the preparation of suppositories, 100 parts by weight of active compound is incorporated in 1300 parts by weight of semi-synthetic glycerides as the 5 suppository base and the mixture formed into suppositories each containing 100 mg of active ingredient.

Example Y

In the preparation of capsules, 50 parts by weight 10 of active compound, 300 parts by weight of lactose and 3 parts by weight of magnesium stearate are de-aggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing 50 mg of active ingredient.


15 Example Z

The active compound is incorporated into the base by thorough homogenization until the drug is evenly distributed. The ointment is packed into 10 g amber jars with screw-capped lined lids.

20 Active compound 0.1 g
 White soft paraffin to 10 g

CLAIMS

1. Compounds of formula I



and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or 5 C-R₃;

R₁ represents hydrogen, halo, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxy carbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxy carbonyl 10 C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxy carbonyl group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄ alkenyl group;

R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ 15 alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which may be substituted by a C₁₋₆ alkanoyloxy group), or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);

R₃ represents hydrogen or a C₁₋₄ alkyl group;

R₄ represents hydrogen, halo, a C₂₋₇ alkoxy carbonyl group, cyano, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a 25 C₁₋₄ alkoxy group), a C₁₋₆ alkyl group [optionally


- 69 -

substituted by one or more hydroxy groups and or an amino group of formula $-\text{NR}_x\text{R}_y$ (in which R_x and R_y independently represent hydrogen or a C_{1-4} alkyl group or R_x and R_y together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a carboxy group, a C_{1-6} alkylthio group or a carbamoyl group of formula $-\text{CONR}_a\text{R}_b$ [in which R_a and R_b independently represent hydrogen, a C_{1-6} alkyl group (optionally substituted by an amino group of formula $-\text{NR}_c\text{R}_d$ in which R_c and R_d independently represent hydrogen or a C_{1-4} alkyl group or R_c and R_d together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring) or R_a and R_b together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring];


R_5 represents hydrogen or a C_{1-4} alkyl group;

R_9 represents hydrogen or a C_{1-4} alkyl group;


R_{10} represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

20 in which

R_6 represents hydrogen, a C_{1-6} alkyl group [optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula $-\text{NR}_{12}\text{R}_{13}$ (in which R_{12} and R_{13} independently represent hydrogen or a C_{1-4} alkyl group or R_{12} and R_{13} together with the nitrogen atom to which they are attached form a pyrrolidine ring, a

- 70 -

- morpholine ring or a piperidine ring), a C₂₋₇ alkoxy carbonyl group or a carbamoyl group of formula CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring); a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or an arylalkyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo);
- 15 or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and
- 20 R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxy carbonyl group;

with a first proviso that when

- 25 R₁ represents hydrogen, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxy carbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxy carbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxy carbonyl group or a C₁₋₆ alkanoylamino group; and

R₂ represents hydrogen, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group, or a phenoxy group


- 71 -

(optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

R₄ represents hydrogen, halo, a C₂₋₇ alkoxy carbonyl group, a benzyloxy carbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), carbamoyl, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ hydroxyalkyl group or a C₁₋₆ alkylthio group; and

10 R₅ represents hydrogen or a C₁₋₄ alkyl group; and

R₁₀ represents a group of formula (1)



(1)

in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or a benzyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

- 72 -

R₇ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, or a C₁₋₆ alkoxy group; and


R₈ represents hydrogen, halo, trifluoromethyl,
5 trifluoromethoxy, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

R₉ represents hydrogen or a C₁₋₄ alkyl group
and B represents N

then A is other than CR₃ in which R₃ represents hydrogen
10 or a C₁₋₄ alkyl group

and a second proviso that when A represents N and B
represents CH; R₁ represents halo or a halogenated C₁₋₆
alkyl group; R₂, R₄, R₅ and R₉ each represent hydrogen
then R₁₀ is other than 4-hydroxyphenyl.

15 2. Compounds according to Claim 1 represented by
formula IIa



in which


R₁ represents hydrogen, halo, a C₁₋₆ alkyl group,
hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆
20 alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl
group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl
C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated
C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl
group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄
25 alkenyl group;

- 73 -


R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ alkoxy group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which may be substituted by a C₁₋₆ alkanoyloxy group), or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);

R₄ represents hydrogen, carbamoyl, a C₂₋₇ alkoxycarbonyl group or cyano; and


R₁₀ represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

10 in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C₂₋₇ alkoxycarbonyl group or a carbamoyl group of formula CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or an arylalkyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy

- 74 -


group), or a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo);

5 or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and

10 R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxycarbonyl group.

3. Compounds according to Claim 2 in which
 R₁ represents hydrogen or chloro;
- 15 R₂ represents hydrogen, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group or phenoxy;
 R₄ represents hydrogen or a C₂₋₅ alkoxycarbonyl group;
 and
 R₁₀ represents 4-methoxyphenyl, 4-(2-pyridyloxyphenyl),
 20 2-ethoxy-5-pyridyl, 4-(2-hydroxyethoxy)phenyl, [4-(β-D-galactopyranosyl)phenyl, 4-(2,3-dihydroxypropoxy)phenyl or 3-ethoxycarbonyl-4-hydroxyphenyl.

4. Compounds according to Claim 1 represented by formula IIb



- 75 -


in which

R₁ represents hydrogen, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group or a carbamoyl C₂₋₄ alkenyl group;


R₂ represents hydrogen, a C₁₋₄ alkoxy group or 5 acetoxyacetoxy;

R₄ represents hydrogen, a C₂₋₇ alkoxycarbonyl group, cyano or carbamoyl; and


R₁₀ represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

in which

10 R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to 15 which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C₂₋₇ alkoxycarbonyl group or a carbamoyl group of formula CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together 20 with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring)]; a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ 25 alkyl group or an arylalkyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo);

- 76 -

or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and

R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxycarbonyl group.


10 5. Compounds according to Claim 4 in which R₁ represents hydrogen, a C₁₋₃ alkyl group or a C₁₋₃ alkoxy group;

R₂ represents a C₁₋₄ alkoxy group;

15 R₄ represents cyano, carbamoyl or a C₂₋₅ alkoxycarbonyl group; and

R₁₀ represents 4-methoxyphenyl, 6-ethoxy-3-pyridyl, 6-hydroxy-3-pyridyl, 6-ethoxy-2-pyridyl, 4-(carbamoylmethoxy)phenyl, 2,4-dihydroxy-5-pyrimidinyl, 2-(pyrid-3-yloxy)pyrid-5-yl, 2-phenoxy-5-pyridyl, 4-20 (ethoxycarbonylmethoxy)phenyl, 3-ethoxy-carbonyl-4-hydroxyphenyl, 4-(2-pyridyloxy)phenyl, 4-(β-D-lactopyranosyl)phenyl or 4-(β-D-galactopyranosyl)-phenyl.

25 6. Compounds according to Claim 1 represented by formula IIc



IIc

- 77 -

in which

R₁ represents hydrogen, a C₁₋₄ alkyl group or a C₁₋₄ alkoxy group;

R₂ represents hydrogen or a C₁₋₄ alkoxy group; and

5 R₄ represents hydrogen or a C₂₋₅ alkoxycarbonyl group.


7. Compounds according to Claim 6 in which

R₁ represents hydrogen or a C₁₋₄ alkyl group;

R₂ represents hydrogen, methoxy, ethoxy or propoxy; and

10 R₄ represents hydrogen, methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl.

8. Compounds of formula I represented by formula IIId



in which

R₁ represents hydrogen, a C₁₋₄ alkyl group or a C₁₋₄ alkoxy group;

15 R₂ represents hydrogen or a C₁₋₄ alkoxy group;

R₄ represents hydrogen or a C₂₋₅ alkoxycarbonyl group and

R₆ represents hydrogen or a C₁₋₄ alkyl group.

9. Compounds according to Claim 8 in which

20 R₁ represents hydrogen, methyl, ethyl or ethoxy;

R₂ represents hydrogen, methoxy, ethoxy or propoxy;

- 78 -

R_4 represents hydrogen, methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl; and

R_6 represents hydrogen, methyl, ethyl or propyl.

10. A compound according to claim 1 selected from
 5 ethyl 6-ethoxy-4-(4-methoxyanilino)-1,5-naphthyridine-3-carboxylate

ethyl 6-ethoxy-4-[4-(2-hydroxyethoxy)anilino]-1,5-naphthyridine-3-carboxylate

10 ethyl 6-ethoxy-4-[4-(β -D-galactopyranosyl)anilino]-1,5-naphthyridine-3-carboxylate


ethyl 7-(2-carbamoylvinyl)-6-ethoxy-4-(4-methoxyanilino)-1,8-naphthyridine-3-carboxylate

ethyl 7-ethoxy-4-(2-ethoxy-5-pyridylamino)-1,8-naphthyridine-3-carboxylate

15 ethyl 7-methyl-4[4-(2-pyridyloxy)-anilino]-1,8-naphthyridine-3-carboxylate

and pharmaceutically acceptable salts thereof.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of
 20 formula I



and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C-R₃;

25 R_1 represents hydrogen, halo, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆

- 79 -

alkoxycarbonyl C₂-4 alkenyl group, a hydroxy C₁-6 alkyl group, a carboxy C₁-4 alkyl group, a C₂-6 alkoxycarbonyl C₁-4 alkyl group, a C₁-6 alkoxy group, a halogenated C₁-6 alkyl group, a carboxy group, a C₂-6 alkoxycarbonyl 5 group, a C₁-6 alkanoylamino group or a carbamoyl C₂-4 alkenyl group;

R₂ represents hydrogen, a C₁-6 alkyl group, halo, a C₁-6 alkoxy group, hydroxy, a C₁-6 alkanoyloxy group (which may be substituted by a C₁-6 alkanoyloxy group), or a 10 phenoxy group (optionally substituted by a C₁-4 alkyl group, halo or a C₁-4 alkoxy group);

R₃ represents hydrogen or a C₁-4 alkyl group;


R₄ represents hydrogen, halo, a C₂-7 alkoxycarbonyl group, cyano, a benzyloxycarbonyl group (optionally 15 substituted by a C₁-4 alkyl group, halo or a C₁-4 alkoxy group), a C₁-6 alkanoyl group, a benzoyl group (optionally substituted by a C₁-4 alkyl group, halo or a C₁-4 alkoxy group), a C₁-6 alkyl group [optionally substituted by one or more hydroxy groups and/or an 20 amino group of formula -NR_xR_y (in which R_x and R_y independently represent hydrogen or a C₁-4 alkyl group or R_x and R_y together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a carboxy group, a C₁-6 25 alkylthio group or a carbamoyl group of formula -CONR_aR_b [in which R_a and R_b independently represent hydrogen, a C₁-6 alkyl group (optionally substituted by an amino group of formula -NR_cR_d in which R_c and R_d independently represent hydrogen or a C₁-4 alkyl group or R_c and R_d 30 together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring) or R_a and R_b together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring];

- 80 -


R_5 represents hydrogen or a C_{1-4} alkyl group;

R_9 represents hydrogen or a C_{1-4} alkyl group;


R_{10} represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

in which

- 5 R_6 represents hydrogen, a C_{1-6} alkyl group [optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula- $NR_{12}R_{13}$ (in which R_{12} and R_{13} independently represent hydrogen or a C_{1-4} alkyl group or R_{12} and R_{13} together with the nitrogen atom to
- 10 which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C_{2-7} alkoxy carbonyl group or a carbamoyl group of formula $CONR_{14}R_{15}$ (in which R_{14} and R_{15} independently represent hydrogen or a C_{1-6} alkyl group or R_{14} and R_{15} together with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring)]; a C_{3-12} alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C_{1-4} alkyl group, halo or a C_{1-4} alkoxy group), a C_{3-6} cycloalkyl C_{1-4}
- 15 alkyl group or an arylalkyl group (optionally substituted by a C_{1-4} alkyl group, halo or a C_{1-4} alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C_{1-4} alkyl group, a C_{1-4} alkoxy group, hydroxy or halo);
- 20 25 or when R_{10} represents a group of formula (1) OR_6 represents a monosaccharide group or a disaccharide

- 81 -

group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and

R₇ and R₈ independently represent hydrogen, hydroxy,
5 halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxycarbonyl group;

with the proviso that when

R₁ represents hydrogen, a C₁₋₆ alkyl group, hydroxy, a
10 carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group or a
15 C₁₋₆ alkanoylamino group; and


R₂ represents hydrogen, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group, or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

20 R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), carbamoyl, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ hydroxyalkyl group or a C₁₋₆ alkylthio group; and
25

R₅ represents hydrogen or a C₁₋₄ alkyl group; and

R₁₀ represents a group of formula (1)

- 82 -



(1)

in which

- R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or a benzyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

- R₇ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, or a C₁₋₆ alkoxy group; and


- R₈ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

- R₉ represents hydrogen or a C₁₋₄ alkyl group and B represents N

then A is other than CR₃ in which R₃ represents hydrogen or a C₁₋₄ alkyl group;

- together with a pharmaceutically acceptable diluent or carrier.

12. The use of a compound of formula I



and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C-R₃;

- 5 R₁ represents hydrogen, halo, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated 10 C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄ alkenyl group;


- R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which 15 may be substituted by a C₁₋₆ alkanoyloxy group), or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);

R₃ represents hydrogen or a C₁₋₄ alkyl group;


- R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl 20 group, cyano, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkyl group [optionally 25 substituted by one or more hydroxy groups and/or an amino group of formula -NR_xR_y (in which R_x and R_y

- 84 -


- independently represent hydrogen or a C₁₋₄ alkyl group or R_x and R_y together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a carboxy group, a C₁₋₆ alkylthio group or a carbamoyl group of formula -CONR_aR_b [in which R_a and R_b independently represent hydrogen, a C₁₋₆ alkyl group (optionally substituted by an amino group of formula -NR_cR_d in which R_c and R_d independently represent hydrogen or a C₁₋₄ alkyl group or R_c and R_d together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring) or R_a and R_b together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring];
- 15 R₅ represents hydrogen or a C₁₋₄ alkyl group;
- R₉ represents hydrogen or a C₁₋₄ alkyl group;
- R₁₀ represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

in which

- R₆ represents hydrogen, a C₁₋₆ alkyl group (optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C₂₋₇ alkoxy carbonyl group or a carbamoyl group of formula

- 85 -

CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring); a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or an arylalkyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo);

or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and

R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxy carbonyl group;

with the proviso that when

R₁ represents hydrogen, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxy carbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxy carbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxy carbonyl group or a C₁₋₆ alkanoylamino group; and


R₂ represents hydrogen, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group, or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

- 86 -

R₄ represents hydrogen, halo, a C₂₋₇ alkoxy carbonyl group, a benzyl oxy carbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), carbamoyl, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ hydroxy alkyl group or a C₁₋₆ alkylthio group; and

R₅ represents hydrogen or a C₁₋₄ alkyl group; and

R₁₀ represents a group of formula (1)



(1)

in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or a benzyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

R₇ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, or a C₁₋₆ alkoxy group; and

- 87 -


R₈ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

R₉ represents hydrogen or a C₁₋₄ alkyl group
5 and B represents N

then A is other than CR₃ in which R₃ represents hydrogen or a C₁₋₄ alkyl group;

as a medicament.

13. The use of a compound of formula I



10 and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C-R₃;

R₁ represents hydrogen, halo, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆
15 alkoxy carbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxy carbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxy carbonyl group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄
20 alkenyl group;

R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which may be substituted by a C₁₋₆ alkanoyloxy group), or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);

- 88 -

R₃ represents hydrogen or a C₁₋₄ alkyl group;


R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, cyano, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkyl group [optionally substituted by one or more hydroxy groups and/or an amino group of formula -NR_xR_y (in which R_x and R_y independently represent hydrogen or a C₁₋₄ alkyl group or R_x and R_y together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a carboxy group, a C₁₋₆ alkylthio group or a carbamoyl group of formula -CONR_aR_b [in which R_a and R_b independently represent hydrogen, a C₁₋₆ alkyl group (optionally substituted by an amino group of formula -NR_cR_d in which R_c and R_d independently represent hydrogen or a C₁₋₄ alkyl group or R_c and R_d together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring) or R_a and R_b together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring];

R₅ represents hydrogen or a C₁₋₄ alkyl group;


25 R₉ represents hydrogen or a C₁₋₄ alkyl group;

R₁₀ represents a group of formula 1, 2 or 3:


- 89 -



(1)



(2)



(3)

in which

R_6 represents hydrogen, a C_{1-6} alkyl group [optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula- $NR_{12}R_{13}$ (in which R_{12} and R_{13} independently represent hydrogen or a C_{1-4} alkyl group or R_{12} and R_{13} together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C_{2-7} alkoxy carbonyl group or a carbamoyl group of formula 5 $CONR_{14}R_{15}$ (in which R_{14} and R_{15} independently represent hydrogen or a C_{1-6} alkyl group or R_{14} and R_{15} together with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring)]; a C_{3-12} alicyclic hydrocarbon group, a phenyl 10 group (optionally substituted by a C_{1-4} alkyl group, halo or a C_{1-4} alkoxy group), a C_{3-6} cycloalkyl C_{1-4} alkyl group or an arylalkyl group (optionally substituted by a C_{1-4} alkyl group, halo or a C_{1-4} alkoxy group); a pyridyl group (optionally substituted by one 15 or more of the following: a C_{1-4} alkyl group, a C_{1-4} alkoxy group, hydroxy or halo); 20

or when R_{10} represents a group of formula (1) OR_6 represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the 25 following: oxidation; oxidation followed by esterification; esterification or acetalisation); and


- 90 -

R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxycarbonyl group;

5 with the proviso that when

- R₁ represents hydrogen, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group or a C₁₋₆ alkanoylamino group; and
- 10 R₂ represents hydrogen, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group, or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and
- 15 R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), carbamoyl, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ hydroxyalkyl group or a C₁₋₆ alkylthio group; and
- 20 R₅ represents hydrogen or a C₁₋₄ alkyl group; and
- 25 R₁₀ represents a group of formula (1)

- 91 -



(1)

in which

- R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or a benzyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

- R₇ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, or a C₁₋₆ alkoxy group; and


- R₈ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

- R₉ represents hydrogen or a C₁₋₄ alkyl group
and B represents N

then A does not represent CR₃ in which R₃ represents hydrogen or a C₁₋₄ alkyl group;

in the treatment of rheumatic diseases.

14. The use of a compound of formula I



and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C-R₃;

- 5 R₁ represents hydrogen, halo, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄ alkenyl group;


- 10 R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which may be substituted by a C₁₋₆ alkanoyloxy group), or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);

R₃ represents hydrogen or a C₁₋₄ alkyl group;


- 15 R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, cyano, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkyl group [optionally substituted by one or more hydroxy groups and/or an amino group of formula -NR_xR_y (in which R_x and R_y

- 93 -


- independently represent hydrogen or a C₁₋₄ alkyl group or R_x and R_y together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a carboxy group, a C₁₋₆ alkylthio group or a carbamoyl group of formula -CONR_aR_b [in which R_a and R_b independently represent hydrogen, a C₁₋₆ alkyl group (optionally substituted by an amino group of formula -NR_cR_d in which R_c and R_d independently represent hydrogen or a C₁₋₄ alkyl group or R_c and R_d together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring) or R_a and R_b together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring];
15. R₅ represents hydrogen or a C₁₋₄ alkyl group;
- R₉ represents hydrogen or a C₁₋₄ alkyl group;
- R₁₀ represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

in which

- R₆ represents hydrogen, a C₁₋₆ alkyl group (optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C₂₋₇ alkoxy carbonyl group or a carbamoyl group of formula

- 94 -

CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring); a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or an arylalkyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo);

or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and

R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxycarbonyl group;

with the proviso that when

R₁ represents hydrogen, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group or a C₁₋₆ alkanoylamino group; and


R₂ represents hydrogen, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group, or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

- 95 -

R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), carbamoyl, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ hydroxyalkyl group or a C₁₋₆ alkylthio group; and

R₅ represents hydrogen or a C₁₋₄ alkyl group; and

R₁₀ represents a group of formula (1)



(1)

10 in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or a benzyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

R₇ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, or a C₁₋₆ alkoxy group; and

- 96 -


R₈ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

R₉ represents hydrogen or a C₁₋₄ alkyl group
5 and B represents N

then A is other than CR₃ in which R₃ represents hydrogen or a C₁₋₄ alkyl group;

in the manufacture of a medicament for use in the treatment of rheumatic diseases.

- 10 15. A method of treating rheumatic diseases, comprising the administration of a therapeutically effective amount of a compound of formula I



- and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C-R₃;
15

R₁ represents hydrogen, halo, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl 20 C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄ alkenyl group;

R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which

- 97 -

may be substituted by a C₁₋₆ alkanoyloxy group), or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);

R₃ represents hydrogen or a C₁₋₄ alkyl group;

5 R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, cyano, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a
10 C₁₋₄ alkoxy group), a C₁₋₆ alkyl group [optionally substituted by one or more hydroxy groups and/or an amino group of formula -NR_xR_y (in which R_x and R_y independently represent hydrogen or a C₁₋₄ alkyl group or R_x and R_y together with the nitrogen atom to which
15 they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a carboxy group, a C₁₋₆ alkylthio group or a carbamoyl group of formula -CONR_aR_b [in which R_a and R_b independently represent hydrogen, a C₁₋₆ alkyl group (optionally substituted by an amino
20 group of formula -NR_cR_d in which R_c and R_d independently represent hydrogen or a C₁₋₄ alkyl group or R_c and R_d together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring) or R_a and R_b together with the nitrogen
25 atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring];

R₅ represents hydrogen or a C₁₋₄ alkyl group;


R₉ represents hydrogen or a C₁₋₄ alkyl group;

R₁₀ represents a group of formula 1, 2 or 3:


30 in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy,


- 98 -



(1)



(2)



(3)


- halo, an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C₂₋₇ alkoxy carbonyl group or a carbamoyl group of formula CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together with the nitrogen to which they are attached form a 5 pyrrolidine ring, a morpholine ring or piperidine ring); a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or an arylalkyl group (optionally 10 substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo); 15
- or when R₁₀ represents a group of formula (1) OR₆ 20 represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and
- R₇ and R₈ independently represent hydrogen, hydroxy, 25 halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxy carbonyl group;

- 99 -

with the proviso that when

- R₁ represents hydrogen, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy 5 C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group or a C₁₋₆ alkanoylamino group; and
- R₂ represents hydrogen, halo, a C₁₋₆ alkoxy group, 10 hydroxy, a C₁₋₆ alkanoyloxy group, or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and
- R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, a benzyloxycarbonyl group (optionally substituted 15 by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), carbamoyl, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ hydroxyalkyl group or a C₁₋₆ alkylthio group; and
- 20 R₅ represents hydrogen or a C₁₋₄ alkyl group; and

R₁₀ represents a group of formula (1)



(1)

in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy,

- 100 -

halo or an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a
5 morpholine ring or a piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or a benzyl group (optionally substituted by a C₁₋₄ alkyl group,
10 halo or a C₁₋₄ alkoxy group); and

R₇ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, or a C₁₋₆ alkoxy group; and


R₈ represents hydrogen, halo, trifluoromethyl,
15 trifluoromethoxy, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

R₉ represents hydrogen or a C₁₋₄ alkyl group and B represents N

then A is other than CR₃ in which R₃ represents hydrogen
20 or a C₁₋₄ alkyl group;

to a mammal in need thereof.

16. A process to prepare a compound of formula I



and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or
25 C-R₃;

- 101 -

- R₁ represents hydrogen, halo, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl 5 C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group, a C₁₋₆ alkanoylamino group or a carbamoyl C₂₋₄ alkenyl group;
- R₂ represents hydrogen, a C₁₋₆ alkyl group, halo, a C₁₋₆ 10 alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group (which may be substituted by a C₁₋₆ alkanoyloxy group), or a phenoxy group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group);
- R₃ represents hydrogen or a C₁₋₄ alkyl group;
- R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, cyano, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a 15 C₁₋₄ alkoxy group), a C₁₋₆ alkyl group [optionally substituted by one or more hydroxy groups and/or an amino group of formula -NR_xR_y (in which R_x and R_y independently represent hydrogen or a C₁₋₄ alkyl group or R_x and R_y together with the nitrogen atom to which 20 they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a carboxy group, a C₁₋₆ alkylthio group or a carbamoyl group of formula -CONR_aR_b [in which R_a and R_b independently represent hydrogen, a C₁₋₆ alkyl group (optionally substituted by an amino 25 group of formula -NR_cR_d in which R_c and R_d independently represent hydrogen or a C₁₋₄ alkyl group or R_c and R_d together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring) or R_a and R_b together with the nitrogen 30


- 102 -

atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring];


R₅ represents hydrogen or a C₁₋₄ alkyl group;

R₉ represents hydrogen or a C₁₋₄ alkyl group;


5 R₁₀ represents a group of formula 1, 2 or 3:



(1)



(2)



(3)

in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo, an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring), a C₂₋₇ alkoxycarbonyl group or a carbamoyl group of formula CONR₁₄R₁₅ (in which R₁₄ and R₁₅ independently represent hydrogen or a C₁₋₆ alkyl group or R₁₄ and R₁₅ together with the nitrogen to which they are attached form a pyrrolidine ring, a morpholine ring or piperidine ring)]; a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or an arylalkyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); a pyridyl group (optionally substituted by one or more of the following: a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, hydroxy or halo);

- 103 -

or when R₁₀ represents a group of formula (1) OR₆ represents a monosaccharide group or a disaccharide group (optionally derivatised by one or more of the following: oxidation; oxidation followed by esterification; esterification or acetalisation); and

R₇ and R₈ independently represent hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ alkoxy group, or a C₂₋₇ alkoxycarbonyl group;

10 with the proviso that when

R₁ represents hydrogen, a C₁₋₆ alkyl group, hydroxy, a carboxy C₂₋₄ alkenyl group, a C₂₋₆ alkoxycarbonyl C₂₋₄ alkenyl group, a hydroxy C₁₋₆ alkyl group, a carboxy C₁₋₄ alkyl group, a C₂₋₆ alkoxycarbonyl C₁₋₄ alkyl group, a C₁₋₆ alkoxy group, a halogenated C₁₋₆ alkyl group, a carboxy group, a C₂₋₆ alkoxycarbonyl group or a C₁₋₆ alkanoylamino group; and


R₂ represents hydrogen, halo, a C₁₋₆ alkoxy group, hydroxy, a C₁₋₆ alkanoyloxy group, or a phenoxy group 20 (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

R₄ represents hydrogen, halo, a C₂₋₇ alkoxycarbonyl group, a benzyloxycarbonyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a 25 C₁₋₆ alkanoyl group, a benzoyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), carbamoyl, a C₁₋₆ alkyl group, a carboxy group, a C₁₋₆ hydroxyalkyl group or a C₁₋₆ alkylthio group; and

R₅ represents hydrogen or a C₁₋₄ alkyl group; and

30 R₁₀ represents a group of formula (1)

- 104 -



(1)

in which

R₆ represents hydrogen, a C₁₋₆ alkyl group [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula-NR₁₂R₁₃ (in which R₁₂ and R₁₃ independently represent hydrogen or a C₁₋₄ alkyl group or R₁₂ and R₁₃ together with the nitrogen atom to which they are attached form a pyrrolidine ring, a morpholine ring or a piperidine ring)], a C₃₋₁₂ alicyclic hydrocarbon group, a phenyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group), a C₃₋₆ cycloalkyl C₁₋₄ alkyl group or a benzyl group (optionally substituted by a C₁₋₄ alkyl group, halo or a C₁₋₄ alkoxy group); and

R₇ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group, a carboxy group, or a C₁₋₆ alkoxy group; and

R₈ represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

R₉ represents hydrogen or a C₁₋₄ alkyl group
and B represents N

then A is other than CR₃ in which R₃ represents hydrogen or a C₁₋₄ alkyl group

- 105 -


and with a second proviso when A represents N and B represents CH; R₁ represents halo or a halogenated C₁₋₆ alkyl group; R₂, R₄, R₅ and R₉ each represent hydrogen then R₁₀ is other than 4-hydroxyphenyl

5 comprising:

a) reacting a compound of formula III




in which R₂₅ represents a leaving group with a compound of formula IV



10 or a salt thereof by heating, optionally in the presence of an inert organic liquid which is preferably a solvent for the reactants, at a temperature in the range 0-150°C, preferably in the range 30-120°C, at atmospheric pressure, optionally in the presence of an acid, or a base; or

15 b) reacting a compound of formula XVII

- 106 -



X V I I

in which R_{20} represents a leaving group with an alkali metal C_{1-6} alkoxide, by heating optionally in the presence of an inert organic liquid which is preferably a solvent for the reactants, at a temperature in the
 5 range $50-250^{\circ}C$ preferably $150-200^{\circ}C$ preferably in a sealed vessel under pressure, to give a compound of formula I in which R_1 represents a C_{1-6} alkoxy group; or
 c) displacing R_{20} from a compound of formula XVII, in
 10 which R_{20} represents a leaving group, by reaction with an alkali metal hydroxide in the presence of an inert organic liquid or by hydrolysis using an aqueous acid or base, at a temperature in the range $0-200^{\circ}C$ to give a compound of formula I in which R_{20} represents hydroxy.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 94/01923

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 5 C07D471/04 C07H15/26 A61K31/435 A61K31/495 A61K31/505
 A61K31/70 //((C07D471/04, 221:00, 221:00), (C07D471/04, 241:00,
 221:00))

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D A61K C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PHARMACOLOGICAL RESEARCH COMMUNICATIONS, vol.11, no.2, 1979, LONDON, GB pages 179 - 193 R. DUANE SOFIA ET AL. 'Comparative effects of antiarthritic and other carrageean edema tests in rats' see table II, line 1; page 184, lines 22 - 25 and page 188, lines 1 - 13 ---	1,14
X	EP,A,0 410 762 (ELI LILLY) 30 January 1991 see claim 1 ---	1
P,A	WO,A,93 13097 (THE BOOTS CO) 8 July 1993 see claims 1,19 cited in the application -----	1,14

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

1

Date of the actual completion of the international search

21 September 1994

Date of mailing of the international search report

- 3. 10. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/01923

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 15 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 94/01923

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0410762	30-01-91	AU-B-	634561	25-02-93
		AU-A-	5982590	31-01-91
		JP-A-	3086881	11-04-91
		US-A-	5240916	31-08-93
-----	-----	-----	-----	-----
WO-A-9313097	08-07-93	AU-B-	3158793	28-07-93
		CA-A-	2125858	08-07-93
		FI-A-	943019	22-06-94
-----	-----	-----	-----	-----

THIS PAGE BLANK (USPTO)